DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   1 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 A Phase 1 , Randomized , Double -Blind, Multi -Site, Single Dose 
Escalatio n Study to Evaluate the Safety, Pharmacokinetics, and 
Immunogenicity of SAR440894 v s Placebo in Healthy Adults  
DMID Protocol Number: 18 -0006 
DMID Funding Mechanism:  Early Phase Clinical Trial Units  
Pharmaceutical Support: Evotec  International  
Other Identifying Numbers:  Task Area C: 18-0006. C1.0143 
IND Sponsor: Division of Microbiology and Infectious Diseases, National Institute of 
Allergy and Infectious Dis eases, National Institutes of Health, US Department of Health 
and Human Services  
 
Draft or Version Number: 11.0 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   2 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 STATEMENT OF ASSURANCE  
Each Institution will hold a current Federal wide Assurance (FWA) issued by the Office of 
Human Research Protections (OHRP) for federally funded  human subjects research. Each FWA 
will designate at least one Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) registered with OHRP, for whic h the research will be reviewed and approved by the 
IRB/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated 
under an FWA may include an institution’s IRB/IEC, an independent IRB/IEC, or an IRB/IEC of 
another institution  after establishing a written agreeme nt with that other institution.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   3 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 STATEMENT OF COMPLIANCE  
The study  trial will be carried out in accordance with Good Clinical Practice (GCP)  and as 
required by the following:  
• United States Code of Federal Regulations (CFR ) 45 CFR Part 46 : Protection of Human 
Subjects  
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50  
(Protection of Human Subjects) , 21 CFR Part 54 (Financial Disclosure by Clinical 
Investigators) , 21 CFR Part 56 (Institutional Review Boards) , 21 CFR Part 11 (Electronic 
Records and Electronic Signatures) , and 21 CFR Part 312  (Investigational New Drug 
Application ) 
• The International Council for Harmoni sation  of Technical Requirements for Registration 
of Pharmaceutic als for Human Use (ICH) : “E6(R2 ) Good Clinical Practice : Integrated 
Addendum to ICH E6(R1) Guidance for Industry,” published in the Federal Register (83 
Federal Register 8882 [2018 ]).  
• Belmont Report: Ethical Principles and Guidelines for the Protection of  Human Subjects 
of Research, Report of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving 
Human Subjects, as applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , 
as applicable  
• Applicable Federal, State, and Local Regulations and Guidance  
• Applicable DMID Policies, Guidelines, and Plans to include but not limited to: Clinical 
Quality Management Policy, DMID Guidelines for Clinical Study Product Management, 
Guidelines for Writing Notes to the Study File, Study Product Management Plan (SPMP), 
Clinical Quality Management Plan (CQMP), etc.  
 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   4 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 SIGNATURE PAGE  
The signature below provid es the necessary assurance that this trial will be conducted according 
to all stipulations of the protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations a nd 
ICH E6 Good Clinical Practice (GCP)  guidelines.  
I agree to conduct the study in compliance with GCP and applicable regulatory requirements.  
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol wi thout obtaining the sponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of subjects.  
Site Investigator  Signature : 
Signed:   
 Date:   
 Principal Investigator Signature    
  
   
 Principal Investigator Printed Name    
 
 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   5 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 TABLE OF CONTENTS  
STATEMENT OF ASSURANCE  ................................ ................................ ................................ ...2 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .3 
SIGNATURE PAGE  ................................ ................................ ................................ ....................... 4 
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 5 
LIST OF TABLES  ................................ ................................ ................................ ......................... 11 
LIST OF FIGURES  ................................ ................................ ................................ ....................... 12 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ........ 13 
PROTOCOL SUMMARY  ................................ ................................ ................................ ............. 16 
 KEY ROLES ................................ ................................ ................................ ......................... 19 
 BACKGROUND AND SCIENTIFIC RATIONALE  ................................ .......................... 20 
 Background  ................................ ................................ ................................ ................. 20 
 Scientific Rationale  ................................ ................................ ................................ .....22 
2.2.1  Purpose of Study  ................................ ................................ ............................ 22 
2.2.2  Rationale for Dosage and Dosing Regimen  ................................ ................... 22 
2.2.3  Study Population  ................................ ................................ ............................ 23 
 Potential Risks and Benefits  ................................ ................................ ....................... 23 
2.3.1  Potential Risks  ................................ ................................ ............................... 23 
2.3.2  Potential Benefits  ................................ ................................ ........................... 25 
 STUDY DESIGN, OBJECTIVES AND ENDPOINTS OR OUTCOME MEASURES  .....26 
 Study Design Description  ................................ ................................ ........................... 26 
 Study Objectives  ................................ ................................ ................................ ......... 28 
3.2.1  Primary  ................................ ................................ ................................ ........... 28 
3.2.2  Secondary  ................................ ................................ ................................ .......28 
 Study Endpoints or Outcome Measures  ................................ ................................ .....28 
3.3.1  Primary  ................................ ................................ ................................ ........... 28 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   6 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 3.3.2  Secondary  ................................ ................................ ................................ .......29 
 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT ................................ .......... 30 
 Study Product Description  ................................ ................................ .......................... 30 
4.1.1  Formulation, Packaging, and Labeling  ................................ .......................... 30 
4.1.2  Product Storage and Stability  ................................ ................................ ......... 31 
 Acquisition/Distribution  ................................ ................................ ............................. 31 
 Dosage/Regimen, Preparation, Dispensing and Administration of Study 
Intervention/Investigational Product  ................................ ................................ ......... 32 
 Predetermined Modification of Study Intervention/Investigational Product for an 
Individual Subject  ................................ ................................ ................................ .....33 
 Accountability Procedures for the Study Intervention/Investigational Product(s)  .....33 
 SELECTION OF SUBJECTS AND STUDY ENROLLMENT AND WITHDRAWAL  ....35 
 Eligibility Criteria  ................................ ................................ ................................ .......35 
5.1.1  Subject Inclusion Criteria  ................................ ................................ .............. 35 
5.1.2  Subject Exclusion Criteria  ................................ ................................ ............. 36 
 Withdrawal from the Study, Discontinuation of Study Product, or Study Termination
 ................................ ................................ ................................ ................................ ..39 
5.2.1  Withdrawal from the Study or Discontinuation of the Study Product  ........... 39 
5.2.2  Subject Replacement  ................................ ................................ ...................... 40 
5.2.3  Study Termination  ................................ ................................ ......................... 41 
 STUDY PROCEDURES  ................................ ................................ ................................ ......42 
 Recruitment  ................................ ................................ ................................ ................. 42 
 Screening (Day -45 through Day -2) and Admission to Clinical Site (Day -1) ......... 43 
 Confinement and Infusion (Day 1 through Day 4)  ................................ ..................... 46 
 Outpatient Study Visits  ................................ ................................ ............................... 49 
6.4.1  Follow -up (Day 7 ±1, 14 ±2, 28 ±4, 56 ±4, 84 ±7, 112 ±7)  .......................... 49 
6.4.2  Final Study Visit (Day 150 ±7)  ................................ ................................ ......50 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   7 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 6.4.3  Early Termination Visit (if needed)  ................................ ............................... 51 
 Unscheduled Study Visits  ................................ ................................ ........................... 52 
 Protocol Deviations  ................................ ................................ ................................ ....53 
 DESCRIPTION OF CLINICAL AND LABORATORY EVALUATIONS  ....................... 54 
 Clinical Evaluations  ................................ ................................ ................................ ....54 
7.1.1  Assessment of Concomitant Medications/Treatments Other Than Study 
Product  ................................ ................................ ................................ ........... 56 
7.1.2  Assessment of Subject Compliance with Study Intervention/Investigational 
Product/Investigational Device  ................................ ................................ ......57 
 Laboratory Evaluations  ................................ ................................ ............................... 57 
7.2.1  Clinical Laboratory Evaluations  ................................ ................................ ....57 
7.2.2  Research Assays  ................................ ................................ ............................. 59 
7.2.2.1  Blood Volume  ................................ ................................ ................... 60 
7.2.2.2  Laboratory Specimen Preparation, Ha ndling, and Storage  ............... 60 
7.2.2.3  Laboratory Specimen Shipping  ................................ ........................ 60 
 ASSESSMENT OF SAFETY  ................................ ................................ ............................... 62 
 Assessing and Recording Safety Parameters  ................................ .............................. 62 
8.1.1  Adverse Events  ................................ ................................ .............................. 62 
8.1.1.1  Adverse Events Grading  ................................ ................................ ...63 
8.1.2  Serious Adverse Events  ................................ ................................ ................. 64 
8.1.3.  Suspected Unexpected Serious Adverse Reactions (SUSAR)  ....................... 65 
8.1.4  Unanticipated Problem  ................................ ................................ ................... 66 
 Specification of Safety Parameters  ................................ ................................ ............. 66 
8.2.1  Solicited Events  ................................ ................................ ............................. 67 
8.2.2  Unsolicited Events  ................................ ................................ ......................... 67 
 Reporting Procedures  ................................ ................................ ................................ ..67 
8.3.1  Reporting Serious Adverse Events  ................................ ................................ 67 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   8 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 8.3.2  Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND
 ................................ ................................ ................................ ........................ 68 
8.3.3  Reporting of Pregnancy  ................................ ................................ ................. 68 
 Type and Duration of Follow -up of Subjects After Adverse Events  .......................... 69 
 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings ................................ ................................ ...................... 69 
 Halting Rules  ................................ ................................ ................................ .............. 70 
8.6.1  Sentinel Subject Halting Rules  ................................ ................................ ......71 
8.6.2  Cohort Dose -Escalation Halting Rules (Dosing through Day 14)  ................. 71 
8.6.3  Study Halting Criteria  ................................ ................................ .................... 72 
8.6.4  Infusion Halting Rules  ................................ ................................ ................... 72 
 Safety Oversight (SRC, SMC)  ................................ ................................ .................... 73 
8.7.1  Data and Safety Monitoring Board  ................................ ................................ 73 
8.7.2  Safety Review Committee  ................................ ................................ ............. 74 
8.7.3  Safety Monitoring Committee  ................................ ................................ .......74 
 HUMAN SUBJECTS PROTECTION  ................................ ................................ ................. 75 
 Institutional Review Board/Independent Ethics Committee  ................................ ......75 
 Informed Consent Process  ................................ ................................ .......................... 76 
 Consent for Future Use of Stored Specimens and Data  ................................ ............. 77 
 Exclusion of Women, Minorities, and Children (Special Populations)  ...................... 77 
 Subject Confidentiality  ................................ ................................ ............................... 77 
 Certificate of Confidentiality  ................................ ................................ ...................... 78 
 Costs, Subject Compensation, and Research Related Injuries  ................................ ...79 
 STATISTICAL CONSIDERATIONS  ................................ ................................ ................. 80 
 Study Hypotheses  ................................ ................................ ................................ .......80 
 Sample Size Considerations  ................................ ................................ ....................... 80 
 Treatment Assignment Procedures  ................................ ................................ ............. 80 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   9 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 10.3.1  Randomization Procedures  ................................ ................................ ............ 80 
10.3.2  Masking Procedures  ................................ ................................ ....................... 81 
10.3.3  Breaking the Blind  ................................ ................................ ......................... 82 
 Planned Interim Analyses  ................................ ................................ ........................... 82 
10.4.1  Interim Safety Review  ................................ ................................ ................... 82 
 Final Analysis Plan  ................................ ................................ ................................ .....82 
10.5.1  Safety Analysis Plan  ................................ ................................ ...................... 83 
10.5.1.1  Adverse and Serious Adverse Events  ................................ ............... 83 
10.5.1.2  Clinical Safety Labs, Vital Signs, and Electrocardiograms  .............. 83 
10.5.2  Pharmacokinetic Analysis Plan  ................................ ................................ ......84 
10.5.3  Immunogenicity Analysis Plan  ................................ ................................ ......84 
 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .............. 85 
 QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ................... 86 
 DATA HANDLING AND RECORD KEEPING  ................................ ................................ 87 
 Data Management Responsibilities  ................................ ................................ ............ 87 
 Electronic CRF (eCRF)  ................................ ................................ .............................. 88 
 Data Capture Methods  ................................ ................................ ................................ 88 
 Types of Data  ................................ ................................ ................................ .............. 88 
 Study Records Retention  ................................ ................................ ............................ 88 
 CLINICAL MONITORING  ................................ ................................ ................................ .90 
 PUBLICATION POLICY  ................................ ................................ ................................ ....91 
 LITERATURE REFERENCES  ................................ ................................ ............................ 92 
 APPENDICES  ................................ ................................ ................................ ...................... 93 
 SCHEDULE OF EVENTS  ................................ ................................ ............ 94 
 TOXICITY TABLE  ................................ ................................ ....................... 98 
 LABORATORY AND VITAL SIGNS ELIGIBILITY RANGES AND 
TOXICITY RANGES ................................ ................................ ................................ ......... 101 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   10 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 LABORATORY ELIGIBILITY AND TOXICITY RANGES  ................... 104 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   11 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 LIST OF TABLES  
Table  3-1: Single Ascending Dose Cohorts and Dose Regimens  ................................ ................ 27 
Table  4-1: Study Product Dosage and Regimen  ................................ ................................ .......... 33 
Table  7-1: Clinical Laboratory Evaluations  ................................ ................................ ................. 57 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   12 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 LIST OF FIGURES  
Figure  1-1: Schematic of Study Design  ................................ ................................ ......................... 18 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   13 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 LIST OF ABBREVIATIONS  
ADA  Anti-drug Antibody  
AE Adverse Event  
AUC  Area Underneath the Plasma Concentration Versus Time 
Curve 
AUC last Area Underneath the Plasma Concentration Versus Time 
Curve From Time 0 to the Last Quantifiable Concentration  
BMI  Body Mass Index  
BP Blood Pressure  
CFR  Code of Federal Regulations  
CHIKV  Chikungunya Virus  
CKD -EPI Chronic Kidney Disease Epidemiology Collaboration  
Creatinine Equation  
Cmax Maximum Observed Plasma Concentration  
Cmin Minimum Observed Plasma Concentration  
CMS  Clinical Material Services  
CS Clinically Significant  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, 
NIH, DHHS  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
ET Early Termination  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   14 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 FDA  Food and Drug Administration  
FWA  Federal wide Assurance  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
ICH International Council  for Harmonisation  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
mAb  Monoclonal Antibody  
MedDRA Medical Dictionary for Regulatory Activities  
MM Medical Monitor  
MOP  Manual of Procedures  
MRSD  Maximum Recommended Starting Dose  
NCS  Not Clinically Significant  
NHP  Non-human Primate  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
NOAEL  No Observed Adverse Effect Level  
OHRP  Office for Human Research Protections  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   15 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 OTC  Over -the-counter  
PBPK  Physiological Based Pharmacokinetic  
PI Principal Investigator  
PK Pharmacokinetics  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAP Statistical Analysis Plan  
SDCC  Statistical a nd Data Coordinating Center  
SMC  Safety Monitoring Committee  
SRC  Safety Review Committee  
SOP Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
SWFI Sterile Water for Injection  
TEAE  Treatment -Emergent Adverse Event  
Tmax Time of the Maximum Observed Plasma Concentration  
UP Unanticipated Problem  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   16 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 PROTOCOL SUMMARY  
 
Title:  A Phase 1 , Randomized , Double -Blind, Multi -Site, Single Dose 
Escalation Study to Evaluate the Safety, Pharmacokinetics, and 
Immunogenicity of SAR440894 vs Placebo in Healthy Adults  
Design of the Study:  This is a Phase 1, randomized, double -blind,  multi -site, single 
dose escalation study to evaluate the safety, pharmacokinetic 
(PK), and immunogenicity of 5 dose levels of IV infusion 
SAR440894 vs placebo in healthy adults.  Five cohorts (N=8 
subjects each) will be randomized to SAR440894 (n=6) or 
placebo (n=2 ). 
Single Ascending Dose Cohorts and Dose Regimens  
Cohort  Dose  Number of subjects  
  SAR440894  Placebo  
1 0.3 mg/kg  6 2 
2 1 mg/kg  6 2 
3 3 mg/kg  6 2 
4 10 mg/kg  6 2 
5 20 mg/kg  6 2 
Total Number of Subjects  30 10 
40 
 
Study Phase:  1 
Study Population:  40 healthy male and female subjects; aged 18 -45 years inclusive; 
meeting eligibility criteria  
Number of Sites:  3 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   17 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Description of Study 
Product or Intervention:  • SAR440894 is a fully human monoclonal antibody  
(IgG1) directed against the E2 envelop e protein of 
chikungunya virus  (CHIKV) . 
• SAR440894 will be supplied in glass vials that contain 
lyophilized powder consisting of active pharmaceutical 
ingredi ent (50  mg/m L), 10 mM histidine, 8% sucrose, 
0.02% polysorbate 80 at pH of 5.5 after reconstitution 
with 2.3 mL SWFI ( sterile water for injection). 
Extractable volume is 2 mL at 50  mg/mL (100  mg/vial).  
• Placebo will be supplied in glass vials that contain  
lyophilized  powder consisting of  10 mM histidine, 
8% sucrose, 0.02%  PS80 , at pH of 5.5. The lyophilized 
formulation will be  reconstitute d with 2.3 m L of sterile 
water for injection ( SWFI). Extractable volume is 2 mL. 
Study Objectives : Primary:  
• To determine the safety of single ascending  IV infusion s 
of SAR440894  when administered in healthy adults . 
Secondary:  
• To determine the PK of single ascending  doses of  
60-minute IV  infusion s SAR440894 in healthy adults . 
• To assess the immunogenicity  of single ascending doses 
of 60-minute IV  infusion s SAR440894 in healthy adults . 
Duration of Individual 
Subject Participation:  Approximately 150 days (5 months ), not including Screening 
visit ( completed within 45 days prior to administration of study 
product ) 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   18 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Figure  1-1: Schematic of Study Design  
 Single Ascending Dose  Screening  and Admission to Clinical Site  
Interview and baseline characteristics  
N=40 (5 cohorts of 8 subjects each)  
Time: Pre-dose (Day  -45 to Day  -1) 
IV Infusion  
Single ascending IV doses of SAR440894 from 0.3  to 20 mg /kg (dependent upon 
assigned cohort).  
The 5 cohorts will consist of 8 subjects (6 active, 2 placebo) per cohort, including 2 
sentinel subjects (1 active, 1 placebo)  
Time: On Study (Day 1)  
Pharmacokinetic Measurements  
Blood sampling at  pre-infusion, at the completion of the infusion, and at (relative to 
the end of the infusion): 1 , 4, 8, 12, 24, 48, and 72 hours, and Day 7±1, Day 14  ±2, 
Day 28  ±4, Day 56  ±4, Day 84  ±7, Day 112  ±7, 150  ±7, and ET (if needed)  
Safety Laboratory Testing and Immunogenicity  
Blood Samples will be Collected for:  
Safety : Days -1, 4, 7  ±1, 14  ±2, 28 ±4, 56  ±4, 84  ±7, 112  ±7, 15 0 ±7, ET (if needed)  
Immunogenicity : pre-infusion,  Day 56  ±4, Day 11  2 ±7, Day 150 ±7, and ET (if 
needed)  
Safety Review and Monitoring Committee  
SRC will review combined bli nded safety data for all data up to Day 14 after each 
cohort.  If SRC feels an SMC is warranted, an ad hoc meeting will be schedule d. 
SDCC will p rovide email notification of halting criteria m et/not met after all 
8 subjects enroll and have attended Day 14 visit for each coh ort. DMID MM will 
notify SDCC and team if dose escalation can occur . The SMC will  have an 
organizational meeting and then ad hoc as  necessary.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   19 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 KEY ROLES  
This study is sponsored by DMID. Decisions related to this study will be made by the protocol 
team, which includes representatives from the participating clinical research si tes (principal 
investigators [PIs]), DMID (sponsor),  and Evotec. Key Roles are noted in the protocol -specific 
manual of procedures (MOP).  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   20 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 BACKGROUND AND SCIENTIFIC RATIONALE  
 Background  
Chikungunya virus (CHIKV) is a mosquito -transmitted virus with s ignificant morbidity in 
humans, including arthritis persisting for months to years, and occasionally cardiac , 
gastrointestinal, ophthalmologic,  and neurologic complications .1 Chikungunya virus  has affected 
over 60 countries, with major outbreaks over the past d ecade occurring in the Caribbean, 
Colombia, Bolivia, Brazil, Argentina, Kenya, Pacific Islands, and Pakistan. 1 Accordingly, 
epidemics of CHIKV are a sizable  economic burden and impose a substantial strain  on the 
operational capacities of local health care systems. There is currently no proven prophyla ctic or 
treatment against CHIKV, underscoring the public health need for drugs able to tr eat or prevent 
CHIKV infection.  
SAR440894 is a potent, fully human monoclonal antibody (mAb) (IgG1) direct ed against the 
viral E2 envelop e protein that has pro foundly and rapidly reduced circulating and tissue viral 
levels in  CHIKV -infected  preclinical models. Due to its exp ected long terminal elimination 
half-life ( approximately 4 weeks), SAR440894 has the potential for use both as a prophylactic 
treatment duri ng CHIKV outbreaks and as a targeted therapy to reduce the progression to chronic 
symptoms in patients with  acute CHIKV  infections and disabling arthralgia. The purpose of this 
study is to evaluate the safety, pharmacokinetics  (PK) , and immunogenicity of S AR440894 in 
healthy adult subjects.  
Nonclinical Pharmacology and Toxicology  
The safety of SAR440894 has been studied in in vivo toxicity studies including repeat dose 
studies (3 doses with a week interval between doses followed by a 5 -week recovery period) in 
CD1 mice and non -human primates (NHPs),  and the target organ identified was the kidney in 
CD1 mice.  
Test article –related changes consisting of adverse renal tubular and interstitial inflammation (not 
dose-related in terms of incidence or severit y) were seen in mice, at all doses tested, sacrificed 1 
week after the last dose and were still present after 5 weeks of a recovery period. Therefore, a no 
observed adverse effect level (NOAEL ) in CD1 mice was not identified.  
In order to explore the etiolo gy of these observations, two complementary studies were 
performed that included an assessment of off -target binding of SAR440894 on kidney samples 
from WT CD1 mice by IHC, and evaluation of immune reaction directed against SAR440894 
and the formation of i mmune complexes. Both investigations were negative.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   21 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Based on the low incidence of findings in all mouse treatment groups, their lack of a clear 
dose/exposure -related trend in terms of incidence/severity, and the preserved functionality of the 
organ (no inc reases in blood urea nitrogen and creatinine levels), these findings are considered 
doubtful. In addition, this finding (test article –related changes consisting of adverse renal tubular 
and interstitial inflammation) can be strictly monitored in humans by evaluating blood and urine 
markers of renal function and injury.  
There were no renal microscopic changes in the NHPs . However, mild to moderate, not dose -
related, and transient increases in urine albumin/creatinine ratio and/or total protein/creatinine 
ratio were observed in the majority of males at the end of treatment. Based on the absence of a 
dose relationship, the presence in males only (despite no sex -related differences in terms of 
exposure), no decrease in serum albumin concentration, and no morphol ogical changes, 
glomerular damage was ruled out. None of the findings were considered adverse, and the 
NOAEL was considered to be the top dose of 45 mg/kg, with a Day 15 mean area under neath the 
plasma concentration versus time curve from time 0 to the las t quantifiable concentration 
(AUC last) of 159,000 µg∙h/mL and 153,000 µg∙h/mL for males and females, respectively.  
Pharmacology studies have been conducted in 2 CHIKV  infected  mouse models and 1  CHIKV  
infected  NHP model to determine the therapeutic and prophylactic potential  of SAR440894. 
SAR440894 demonstrated potent activity in the therapeutic approach. In mice, SAR440894 
induced a significant reduction in the viral load in musculoskeletal tissues (>  1 log), a significant 
reduction in p ost-treatment viremia, and a significant reduction in footpad swelling, even when 
CHIKV was already disseminated in distal musculoskeletal tissues. In NHPs, SAR440894 
administered IV efficiently controlled the development of CHIKV disease when administered  at 
the highest doses of 2.5 and 12.5 mg/kg (viremia neutralization, decrease in CHIKV disease 
markers such as inflammatory markers).  
SAR440894 also demonstrated a strong ability to protect animals from CHIKV infection when 
used as a prophylactic agent. In  mice, SAR440894 administered intraperitoneally up to 21 days 
prior to CHIKV challenge induced a significant reduction of viral titer in the right hind limb at 
the site of virus injection and induced an effective reduction of footpad swelling. Prophylactic  IV 
administration of SAR440394 at 0.5, 2.5 , and 12.5 mg/kg in Rhesus Macaque 7 days prior to 
CHIKV infection controlled initial viremia and limited the inflammatory markers of CHIKV 
associated disease.  
In mice receiving a 50 mg /kg IV bolus  SAR440894, maxi mum observed plasma concentration 
(Cmax) was 12 30 µg/mL, clearance was 0.005 L/day/kg, and volume was 0.083 L/kg , with a 
half-life of 12.5 days. In NHP receiving a 2.5 mg/kg  IV bolus, C max was 75.7 µg/mL, clearance 
was 0.002 L/day/kg, and volume was 0.0706  L/kg, with a half -life of 25.5 days . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   22 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 To evaluate the immunogenic potential of SAR440894, peripheral blood mononuclear cells from  
22 healthy human donors were used to evaluate CD4 T -cell activation and cytokine release that  
may act as a potential prelude t o development of anti-drug antibodies ( ADA ). Four of 22  donors 
responded to SAR440894 with a positive response from 1 cytokine  (interferon gamma) . No 
specific increase in immunogenicity p otential was observed in the 16  donors with human 
leukocyte antigen  alleles previously predicted to bind to a T -cell epitope.  These results suggest 
that under the tested  experimental conditions, SAR440894 did not seem to increase the risk of 
T-cell activation and overall, SAR440894 poses a low likelihood of immunog enicity.  
No genotoxicity studies have been conducted with SAR440894 as the antibody is not expected to  
interact directly with DNA or other chromosomal material. In addition, no carcinogenicity 
studies have been performed because SAR440894 will not be used for long-term administration.  
 Scientific  Rationale  
2.2.1 Purpose of Study  
The purpose of the study is to evaluate the safety, PK, and immunogenicity of 5 dose levels of IV 
infusion  SAR440894 vs placebo in healthy adult subjects . No formal hypotheses are being tested 
in this Phase 1 study . 
2.2.2 Rationale for Dosage and Dosing Regimen  
There are no prior clinical studies completed with SAR440894 . In mouse models with early 
infec tion, single doses between 0.5 to 12.5  mg/kg administered intr aperitoneally demonstrated 
significant viral load reduction in musculoskeletal tissues and reduction of  footpad swelling 
(ED50 of 0.75  mg/kg) a nd neutralization of viremia (1  mg/kg dose).  In the same mouse model, 
SAR440894 still induced a significant reduc tion of the virus in musculoskeletal tissues at a dose 
of 2.5  mg/kg when administered later after infection (>  72 hours).  Using CHIKV -infected NHP 
models, IV infusion for SAR440894 at dosages of 0.5 mg/kg, 2.5 mg/kg, and 12.5 mg/kg 
resulted in resolution o f viremia at all dosages and absence of replicative virus in joints and 
tissues at the 2.5 mg/kg and 12.5 mg/kg dosage . Using the mouse and NHP in vivo efficacy 
models, the predicted ef fective therapeutic dose is 2.5  mg/kg and the predicted e ffective 
proph ylactic dose is 1  mg/kg.  
To determine  the starting doses for the study , two approaches were used ( physiological based 
pharmacokinetic  [PBPK ] mode ling and single species allometry). The maximum recommended 
starting dose (MRSD) was chosen to give a target plasma area underneath the plasma concentration 
versus time curve ( AUC ) in humans that is 1/10th the exposure level at the NOAEL from toxicity 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   23 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 studies in NHPs. Both approaches were also used to predict the clearance and dose that would 
result in the same target exposure level in CHIKV infected individuals.  
A PBPK model for SAR440894 was constructed using the Simcyp minimal PBPK model for mAbs 
with 1: 1 FcRn binding, and used the measured FcRn binding affinity as a model input. The 
resulting model for NHPs adequately captured the preclinical half -life and clearance with predicted 
values within 2 -fold of the observed values. The predicted MRSD based on t he human PBPK 
model was 0.83 mg/kg.  
The MRSD was also predicted using single -species allometry using NHP data and allometric 
exponents of 0.5, 0.8, 0.9 and 1.1. The predicted MRSD was 0.29 -1.79 mg/kg and the results from 
the PBPK model fall within this ran ge. In totality, these results support a conservative MRSD of 
0.29 mg/kg.  
The proposed study design allows  for accurate characterization of PK and safety while balancing 
the public health need to advance the development of this product by reducing the overall study 
timeline.  
2.2.3 Study Population  
In this study, healthy adult subjects that meet all eligibility criteria will be included in each 
cohort. As there are no prior clinical studies with SAR440894, a healthy adult population is 
considered appropriate for this first-in-human Phase 1 study . Non-pregnant women and 
minorities will be included in this study.  
 Potential Risks and Benefits  
2.3.1 Potential Risks  
This is the first clinical study of SAR440894 in humans. Nonclinical toxicology of SAR440894  
is presented in Section 2.1. Although no significant risks to humans are anticipated d ue to the 
absence of human target , renal toxicity was observed i n the mouse toxicity study  consisting of 
adverse renal tubular and interstitial inflammation (not dose -related in terms of incidence or 
severity) at all doses. Based on the low incidence of findings in all treatment groups, their lack of 
a clear dose/expos ure-related trend in terms of incidence/severity, and the preserved functionality 
of the organ (no increases in blood urea nitrogen and creatinine) levels, these findings are 
considered doubtful. While no clear mechanism of toxicity was identified in mice, a potential 
risk in humans remains.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   24 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 The NHP study demonstrated a mild increase in total urine  protein/creatinine ratio at 5 and 
15 mg/kg, and a mild to moderate increase in urine albumin/creatinine ratio in males at 15 and 
45 mg/kg. At 45 mg/kg, males also had a mild increase in incidence and severity of 
hematuria/hemoglobinuria. There were no renal  microscopic changes observed in the 
cynomolgus monkey. Test item related changes observed in the urine were considered to be not 
adverse  based on the 1) absence of a dose relationship, 2) the absence of  morphological changes  
in the kidneys or urinary bladders ( glomerular damage was ruled out ), and 3) the transient effects 
(no changes were observed after 5 weeks of washout period) . The NOAEL wa s considered to be 
the top dose of 45 mg/kg, with a Day 15 mean AUC last of 159,000 µg∙h/mL and 
153,000  µg∙h/mL for males and females, respectively.  
As with other monoclonal antibodies , hypersensitivity reactions including anaphylaxis may 
occur immediately or within a few hours of infusion. This may be related to the generation of 
anti-drug antibody ( ADA ). However, such reactions are rare and often associated with mAb s 
targeted to human proteins . In preclinical testing, no ADA was detected in any SAR440894 
animals. In addition, a life -threatening cytokine release syndrome occurred during a first -in-
human study of a superagonist mAb; this was thought to occur due to the rapid release of 
proinflammatory  cytokines from target immune cells. 2 Because SAR440894 is a fully human 
antibody targeted toward viral proteins, we expect the risk of anaphylactic reactions and cytokine 
release syndrome will be very low. Other reactions are generally m ild but may include fever, 
chills, rigors, nausea, vomiting, pain, headache, dizziness, shortness of breath, bronchospasm, 
hypotension, hypertension, pruritus, rash, urticaria, angioedema, diarrhea, tachycardia or chest 
pain. 3 
Delayed hypersensitivity and immune responses secondary t o immune complex formation 
(ie, serum sickness) typically have a subacute presentation. As a result, the association between 
administration of a protein ther apeutic and non -acute reactions may be more difficult to 
establish. Clinical signs may include delayed onset of fever, rash, arthralgia, myalgia, hematuria, 
proteinuria, serositis, central nervous system complications, and hemolytic anemia in the face of 
an ongoing antibody response to the protein therapeutic.  
Other study -related risks include loss of confidentiality and complicatio ns from blood draws . 
The catheters inserted for blood draws could cause clotting, infection , or vein inflammation. The 
risks as sociated with insertion of the catheter and frequent blood draws are pain and bruising.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   25 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 The benefit of the study is expected to outweigh the risk given the balance of the widespread 
prevalence of CHIK V, the morbidity associated with the disease, and the la ck of available 
treatment  with the rea ssuring nonclinical safety data . 
2.3.2 Potential Benefits  
There are no expected direct benefits to healthy subjects participating in this trial. The 
knowledge gained could be of benefit to public health, to individuals with CHIKV , and to 
individuals traveling to areas prone to outbreak.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   26 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 STUDY DESIGN, OBJECTIVES  AND ENDPOINTS OR 
OUTCOME MEASURES  
 Study Design Description  
This is a Phase 1, randomized , double -blind, placebo -controlled, multi -site, single dose 
escalation study to evaluate the safety, PK, and immunogenicity of 5 dose levels of IV 
SAR440894 vs placebo in healthy adults. The study is expected to  enroll  approximately  
40 subjects . 
Subjects in f ive cohorts (N=8 subjects each) will be randomized to SAR440894 (n=6) or placebo 
(n=2  [Table  3-1]). Randomization  and masking procedures are described in detail in 
Section  10.3.1  and Section  10.3.2 , respectively. Subjects will be screened and recruited in to each 
cohort over 4  weeks  prior to the start of the next cohort. Alternate subjects may be included in 
each cohort in order  to facilitate study enrollment as described in Section  6.1. 
In each cohort, 2 sentinel subjects will receive dosing (1 placebo, 1 active) . The enrolling  site 
PI(s) will review safety data through Day 4 to confirm no halting criteria (see Section  8.6.1 ) have 
been met and notify DMID MM prior to dosing the remaining subjects in the cohort. Upon 
approval from the DMID MM, the remaining subjects within each cohor t will be dosed in groups 
of two at least 24 hours apart.  Dosing start times will be staggered by at least 15 minutes 
between subjects. Subjects wi ll remain in confinement for at least  72 hours after receiving study 
product . Thereafter, Follow -up in each c ohort will  occur until 150 ±7 days. This prolonged 
Follow -up period takes into account the long half -life of SAR440894 and will allow for 
appropriate characterization of the PK, safety, and immunogenicity of SAR440894 . Accordingly, 
each cohort will comple te the study approximately 2 2 weeks (150 days) from  randomization  
through Follow -up. 
  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   27 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Table  3-1: Single Ascend ing Dose Cohorts and Dose Regime ns 
Cohort  Dose  Number of Subjects  
  SAR440894  Placebo  
1 0.3 mg/kg  6 2 
2 1 mg/kg  6 2 
3 3 mg/kg  6 2 
4 10 mg/kg  6 2 
5 20 mg/kg  6 2 
Total Number of Subjects  30 10 
40 
 
All laboratory testing for Screening and safety monitoring will be performed at clinical site 
safety laboratories . After signature of the informed consent form  (ICF) , completion of the 
Screening visit, and confirmation of all eligibility criteria, the subject will be admitted to the 
clinical site  1 day before the dose of the study product . The site PI or medically qua lified 
designee will be present at the time of study product  administration and vital signs will be 
monitored per the study protocol  (refer to the Schedule of E vents , Appendix A , and Section  6.3). 
All subjects wi ll remain in confinement from 1  day prior to administration of stud y product  
(Day  -1) until at least 72 hours following dosing with SAR440894 . 
Blinded safety and clinical laboratory data up to the Day 14 visit will be evaluated by the Safety 
Review  Committee (S RC) after each cohort . The safety review will include serious adverse 
events ( SAEs ), AEs, safety clinical laboratory results, electrocardiograms ( ECGs ), and vital 
signs. The SDCC will notify the SRC and study team s via email  if any halting criteria have been 
potentially met af ter each cohort. If none of the predefined halting criteria are met, the DMID 
MM will provide approval for the study to  proceed to the next cohort , or alternatively 
recommend convening of the Safety Monitoring Committee (SMC) . If any of the predefined 
halting criteria are met, study enrol lment and dosing will be stopped until the SMC provides 
recommendations regarding continuation of the study.  Otherwise, the SMC will meet for an 
organizational meeting and ad hoc as appropriate.  Dose -escalation halting rule s are defined in 
Section  8.6.2 . Review  of SAR440894 time-concentration trends may occur following each 
cohort . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   28 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Study assessment s (including the collection of AEs and SAEs) will be performed per the 
Schedule of Events by the  study staff  (Appendix A ). All PK and anti-drug antibody samples will 
be shipped in accordance with the MOP  and shipping will be monitored using  Emmes  
Global Trace sample tracking system to the DMID Clinical Material Services (CMS), Fisher 
BioServices . 
 Study Objectives  
3.2.1 Primary   
• To determine the safety of single ascending IV infusions  of SAR440894  when administered 
in healthy adults . 
3.2.2 Secondary  
• To determine the PK of single ascending doses of  60-minute IV  infusions SAR440894 in 
healthy adults.  
• To assess the immunogenicity of single ascending doses of 60-minute IV  infusion s 
SAR440894 in healthy adults . 
 Study Endpoints or Outcome Measures  
3.3.1 Primary  
• Occurrence of AEs and SAEs following the start of study product  administration through  the 
final visit  (Day 1 50 [±7]), or Early T ermination  (ET) . 
• The occurrence of  clinically significant (CS) changes  from baseline  in vital signs and clinical 
safety laboratory values following administration of  study product through  the final visit 
(Day 150 [±7 ]), or ET. 
• The occurrence of CS changes  in ECG parameters post administration of study product 
through  the final visit ( Day 150 [±7 ]), or ET. 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   29 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 3.3.2 Secondary  
• SAR440894 PK after single ascending doses determined from plasma concentrations 
pre-dose and from the start of infusion until Day 150 (±7), or ET . 
• SAR440894 immunogenicity  determined from presence/absence of plasma human ADA and 
measurement of concentration from  prior to  infusion and at selected time  points after 
infusion up to  Day 150 (±7) or ET . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   30 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 STUDY INTERVENTION /INVESTIGATIONAL 
PRODUCT  
 Study Product Description  
SAR440894 is a fully human mAb  (Type IgG1) directed against the E2 envelop e protein of 
CHIKV including mutations in the Fc part that improve binding to FcRn. The drug substance of 
SAR440894 is produced by cell culture (CHO cells), starting from a cGMP quality cell bank  and 
purified via chromatography steps.  
4.1.1 Formulation, Packaging, and Labeling  
SAR440894  
SAR440894 is supplied as a lyophilized powder that is to be reconstituted with 2.3 m L sterile 
water for injection ( SWFI). Upon reconstitution, a colorless to slightly brownish/yellowish and 
clear to slightly opalescent solution is obtained. The formulation is comprised of  the following 
active pharmaceutical ingredient:  10 mM histidine, 8% sucrose, 0.02% polysorbate 80at a pH of 
5.5. Extractable volume is 2 mL at 50  mg/m L (100 mg/vial).  
Placebo  
Placebo will be supplied as  lyophilized  10 mM histidine, 8% sucrose, 0.02% polysorbate 80 , pH 
of 5.5. Primary packaging is glass vials, to be reconstituted with 2.3 m L of SWFI (extractable 
volume 2 mL).  The reconstituted product is clear and colorless.  
SWFI , USP  
The SWFI, USP is non -pyrogenic and contains no bacteriostatic, antimicrobial agent, or added 
buffer. This product should be used to reconstitute the SAR440894 product. S terile WFI vials 
will be supplied as a single -dose container.  
Each of these  study products will be labeled according to manufacturer and regulatory 
specifications and include the statement “Caution: New Drug – Limited by Federal Law to 
Investigational Use. ” 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   31 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 4.1.2 Product Storage and Stability  
SAR440894  
SAR440894 vials must be stored at 2 °C to 8  °C (36-46 °F) protected from light . Reconstitution 
should be performed at room temperature. Reconstituted product can be kept refrigerated (2 °C 
to 8 °C), if not immediat ely used (do not freeze). The reconstituted study product will be further 
diluted in IV bags containing normal saline. Once diluted, the study product should be stored at 
room temperature and protected from l ight prior to infusion . The total time from the start of the 
reconstitution to the start of the infusion should not exceed 4 hours.  
Placebo  
Vials containing lyophilized  placebo  must be stored betwee n 2 °C to 8  °C. 
SWFI, USP  
Store at room temperature (20  °C to 25  °C or 68  °F to 77  °F [See USP Control led Room 
Temperature] ). 
 Acquisition/Distribution  
SAR440894  
SAR440894  for injection will be provided by Evotec  and distributed through DMID CMS, 
Fisher BioServices.  
Placebo  
Placebo  for injection  will be provided by  Evotec and distributed through  DMID CMS, Fisher 
BioServices.  
SWFI, USP  
Sterile water for injection will be provided by the site. 
Ancillary supplies  
Ancillary supplies for IV administration, such as infusion sets and sodium chloride IV bags, will 
be provided by the site.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   32 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 Dosage /Regimen , Preparation , Dispensing  and Administration of 
Study Intervention/Investigational Product  
See the protocol -specific MOP for detailed information on the preparation, labeling, storage, and 
administration of study product  for each treatment. Study product preparation will be performed 
by the  unblinded site research pharmacist on the same day as administration  (Table  4-1) as 
outlined in the protocol -specific MOP . Prior to using any of the parenteral products, inspect for 
damage, contamination, discoloration , or particulate matter. Any product that fails inspection 
should be quarantined at 2-8°C and labeled as ‘Do Not Use’ (until further notice). The site PI or 
responsible person should immediately contact t he DMID Product Support Team at 
DMIDProductSupportTeam@niaid.nih.gov  and the DMID Clinical Project Manager for further 
instructions before any additional study product  infusions. Based on the information collected, 
DMID and/or the manufacturer will determine whether the affected study product can be used. If 
it cannot be u sed, the site will receive specific instructions on how to return the affected study 
products to the DMID CMS or destroy it on site  as outlined in the MOP . 
Preparation of the product will be performed using aseptic techniques under a sterile 
environment (e g, biologic safety  cabinet or laminar flow hood ). Based on the subject weight  on 
Day -1 and assigned cohort randomization, the appropriate weight -based dose will be calculated 
and the appropriate number of vials will be removed from storage to prepare the infusion. The 
placebo will be prepared in the same manner as the study product . The SAR440894 and placebo 
should be administered as a single IV infusion, using an infusion pump over 60 minutes. The IV 
administrati on set must contain a 0.2 µm in-line filter . Dose and volume calculations for study 
product  and the placebo will be further described in the protocol -specific MOP.  
The subjects will be admitted to the clinical site  the day before the planned infusion  (Day -1). 
Verification that the subject still me ets all inclusion criteria and does not meet  any exclusion 
criteria must be made prior to randomization.  Administration procedures for the study product, 
including handling of  infusion interruptions, are outlined in the MOP.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   33 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Table  4-1: Study Product Dosage and Regimen  
Product Name  Dose  Route  Frequency of 
Administration  Duration of Infusion  & 
Flush * 
SAR440894  0.3, 1 , 3, 
10, or 20 
mg/kg  IV 
infusion  Once  60 minutes   
[Placebo]   IV 
infusion  Once  60 minutes  
*The targeted infusion duration is 60 minutes, but has an acceptable range of 55 to 70 minutes.  
 Predetermined Modification of Study Intervention/Investigational 
Product for a n Individual  Subject  
Infusion interruptions (up to 1 hour ) may be allowed for non -drug safety related issues  (ie, IV 
infiltration or mechanical difficulties with the pump) . 
 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
Upon receipt of the study product, the site PI is responsible for the distribution and disposition of 
study product and has the ultimate responsibility for accountability. As this is a blinded study, 
the site PI will delegate this responsibility to the unb linded site research pharmacist. The 
unblinded site research pharmacist will be responsible for maintaining complete records and 
documentation of study product receipt,  accountability, dispensation, temperature monitoring, 
storage conditions, and final dis position of the study product.  
Used and unused  investigational product vials will be stored at 2 -8 °C in the investigational 
pharmacy until clinical trial accountability is completed and the sponsor approves of the 
disposition . Any used IV infusion bags and IV administration tubing should be disposed of as 
biohazardous waste per institutional requiremen ts once administration is complete.  
Upon completion of the trial or termination of the study and after the final monitoring visit, any 
remaining unused study drugs will either be returned or destroyed appropriately at the clinical 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   34 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 site in accordance with t he disposition plan provided by the DMID CPM . Refer to the MOP for 
complete drug accountability and monitoring.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   35 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 SELECTION OF SUBJECTS AND STUDY 
ENROLLMENT AND WITHDRAWAL  
 Eligibility Criteria  
No exemptions are granted on subject inclusion/ exclusion criteria  in DMID -sponsored studies. 
Questions about eligibility should  be directed toward the DMID medical officer.  
5.1.1 Subject Inclusion Criteria  
Subjects eligible to participate in this study must be in generally good health and meet all of the 
following inclusion c riteria  at Screening and Day -1: 
1. Must be a healthy adult  18 to 45 years of age, inclusive , with a body mass index ( BMI ) 
greater than 18 or less than 35  kg/m2, inclusive . 
2. Participant s of childbearing potential* having vaginal intercourse must use an effective 
method of contraception** from 45 days before study product  administration through the 
final study visit . 
*Not sterilized via hysterectomy or bilateral oophorectomy  and/or salpingectomy  or be  
less than 1 year from the last menses if menopausal.  
**Includes  any of the following (a) exclusive non -male sexual relationships; (b) 
monogamous relationship with vasectomized partner (≥ 180 days between procedure and 
subject receipt of investigational product); (c)  bilateral tubal ligation or tubal occlusion 
(eg, Essure®); (d) effective intrauterine device (IUD); (e) hormonal implants ( eg, 
Implanon®); (f) other hormonal contraceptives (such as birth control pills, vaginal rings, 
patches or injections); (g) barrier m ethods (condom, diaphragm, cervical cap) PLUS 
spermicide (gel or foam)  
3. Women of childbearing potential must agree not to donate ova or oocytes (ie, human 
eggs) during the study.  
4. Male subjects (including those with  vasectomies) whose partners are of childbe aring 
potential  should use condoms with spermicide  and not donate sperm for the d uration of 
the study . 
5. Must have adequate venous access for IV infusions and blood draws.  
6. Agrees to be available for all study visits and willing to cooperate fully with the 
requirements * of the study protocol . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   36 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 *Requirements includ e remaining in confinement for at least 72 hours after receiving 
study product and other activities outlined in the  Schedule of Events . 
7. Is able to understand the informed consent process and procedures and sign s the consent 
form.  
8. Will agree not to donate any blood or blood products * for the duration of the study.  
*Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives . 
9. Will agree to avoid travel to endemic areas (as de fined by the CDC)  for CHIKV  at any 
point during the Follow -up period  (https://www.cdc.gov/chikungunya/geo/index.html ). 
5.1.2 Subject Exclusion Criteria  
Subjects must NOT meet any of the following exclusion criteria  at Screening and Day -1: 
1. Has any medical condition  (eg, renal dysfunction)  that, in the opinion of the site PI or 
appropriate sub -investigator  listed on Form FDA 1572 , is a contraindication to study 
participation.  
2. Has any CS ECG abnormalities  in the opinion of the site PI or appropriate sub -
inves tigator been listed on Form FDA 1572 . 
3. Use of any  prohibited  prescription medication (excluding contraceptive s in females) 
within 14  days before study product  administration, through Day 56*. 
*Prohibited medications include immunosuppressives; immune modula tors; oral 
corticosteroids (topical/intranasal steroids are acceptable); prescription Non -Steroidal 
Anti-inflammatory Drugs (NSAIDs); anti-neoplastic agents; any vaccine (licensed or 
investigational). If study activities overlap with the influenza season, subjects will be 
instructed to obtain influenza vaccine at least 45 days prior to proposed dosing or delay 
vaccination until after Day  56. Subjects will be instructed  to obtain the last dose of any 
vaccine for SARS -CoV -2 (COVID -19) at least 45 days prior to proposed dosing or delay 
vaccination  until after Day 56.  
4. Use of nonprescription systemic  drugs within 7  days before study product  administration  
(includes vitamins, antacids *, over-the-counter  drugs **, herbal /dietary supplements, etc.)  
through Day 28***. 
*Includes proton pump inhibitors and H2 -blockers  
**Includes oral ana lgesics and anti -inflammatory drugs  
***Nonprescription drugs and supplements may be allowed before Day  28 at the 
discretion of the site PI.  In the event an OTC oral contraceptive becomes available during 
the course of the study, it must be reviewed and approved by the site PI.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   37 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 5. Hypertension, with confirmed systolic blood pressure (BP) greater than 140  mm Hg or 
confirmed diastolic BP greater than 90  mm Hg, measured after 5  minutes of rest at 
Screening.  
6. Hypotension, with confirmed systolic BP <  90 mm Hg.  
7. Resting heart rate (HR) less than 45 bpm or greater than 100  bpm at Screening.  
8. Body weight less than  50 kg. 
9. History of a significant illness , per the investigators’ clinical judgment, within 2  weeks 
before dosing (subjects can screen after illness is resolved for 2  weeks) . 
10. Known diagnosis of prolonged QT interval, congenital long QT syndrome, 
bradyarrhythmias, or uncompensated heart failure.  
11. Males with a mean  QTcF greater than 450  msec or females with a mean  QTcF greater 
than 4 70 msec (Fridericia's correction) at Screening.*  
*ECG tracings sho uld be recorded at least 1 minute apart, after at least 5  minutes of rest 
in the supine position. If the mean  QTcF val ue from the 3  tracings exceeds the limits 
stated, the subject is disqualified.  
12. Any h istory of malignancy  ever,  except low -grade skin cancer (ie, basal cell carcinoma 
thought to be cured).  
13. History of drug  abuse, alcohol abuse , or significant psychiatric history  according to the 
investigator s’ judgment within 12  months before Screening.  
14. Positive for hepatitis B virus surface antige n, hepatitis C virus antibody, or human 
immunodeficiency virus (HIV) antibody  at Screening . 
15. Excessive consumption of beverages containing xanthine bases , or more than 400  mg of 
caffeine per day  within 1 week of study product administration  through the fina l study 
visit.  
16. Consumption of alcohol within 24  hours before study product  administration.  
17. Use of nicotine -containing prod ucts within 45 days before study product administration  
through the final study visit.  
18. Positive drug screen* , positive cotinine screen,  or positive breathalyzer test for alcohol at 
Screening or admission  (Day -1). 
*Cannabinoids, amphetamines, barbiturates, cocaine, opiates, be nzodiazepines and 
phencyclidine. Subjects should be notified by phone not to co nsume any poppy see ds 
within 24  hours before the Screening urine  test to avoid a false positive opioid test result.  
19. If female, serum positive p regnancy test at Screening or serum positive pregnancy test on 
Day -1. 
20. Breastfeeding  throughout the duration of the study . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   38 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 21. Total WBC  and platelet counts, hemoglobin *, total bilirubin *, alanine/aspartate 
aminotransferase * and sodium * are Grade 1 or higher ** at Screening visit ***. 
*For sodium;  potential subjects excluded prior to Protocol Version  6.0 with Grade 1 
sodium values may be rescreened.  
For hemoglobin; a lower limit within 0.5 g/dL of the lower limit of normal (LLN) is 
allowable  at Screening . 
For total bilirubin; ULN  values will be allowed at Screening and Day  -1/baseline  
provided the AST and ALT are within normal limits . Potential subjects excluded prior to 
Protocol Version  6.0 with bilirubin values below the Version  6.0 upper limit may be 
rescreened . 
For ALT/AST; subjects  who screened prior to Protocol Version 11.0 were excluded if 
AST/ALT results were Grade 1 or higher at Screening. Subjects who screen with 
Protocol Version 11.0, AST/ALT is exclusionary if Screening results are 1.5 × ULN or if 
assessed as CS by the site PI. 
**Grade  1 or higher toxicity, see Appendix C  and Appendix D  for subjects  who screened 
and enrolled prior to Protocol Version 11.0. Subjects who screen and enroll with Protocol 
Version 11.0, toxicity will be assessed with the NCI CTCAE, Version 5.0 – 
November  2017 .4 Safety laboratory tests  drawn on Day -1 or Screening if within 48 
hours of planned dosing will serve as baseline values. Day -1 laboratory tests with a 
Grade  1 severity , other than those noted above,  will not exclude subjects from 
participation . 
*** All other abnormal laboratory values collected at Screening and on Day -1 will be 
exclusionary at the discretion of the PI.  
22. Potassium,  bicarbonate , or creatinine /eGFR * results are Grade 1 or higher  at either 
Screening or Day -1/Baseline visits.  
*For creatinine; subjects who screened prior to Protocol Version 11.0 were excluded if 
creatinine results were Grade 1 or higher. Subjects who screen with Protocol Version 
11.0, creatinine is not an exclusionary criteri on, instead subjects should have a cal culated 
eGFR  using Chronic Kidney Disease Epidemiology Collaboration  Creatinine Equation  
(CKD -EPI) of ≥ 90 mL/min/1.73m2 to be enrolled in the study.  
23. Received an experimental agent  (vaccine, drug, biologic, device, or medication ) within 
45 days or 5  half-lives (whichever is longer) before study product  administration .* 
*Prior participation at any time in noninvasive methodology trials in which no drugs 
were given is acceptable . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   39 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 24. Is participating  in or plans to participate in another clinical trial with  an interventional 
agent that will be received during this trial . 
25. Has donated more than 500 mL of blood or blood products * within the month before 
Screening . 
*Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives . 
26. Has a history of  serologically -proven CHIKV  exposure  at any point, or positive 
anti-CHIKV  antibodies  (ie, positive IgM or IgG)  at Screening . 
27. Has rec eived blood products within 120  days prior to Screening . 
28. Has received mAb  in the past  3-months  or 5 half-lives (whichever is  longer)  prior to 
Screening , whether license d or investigational , or plans to receive a mAb outside of this 
study . 
 Withdrawal from the Study, Discontinuation of Study Product, or 
Study Termination  
5.2.1 Withdrawal from the Study or Discontinuation of the Study Product   
Subjects may voluntarily withdraw their consent for study participation at any time without 
penalty or loss of benefits to whic h they are otherwise entitled.  
An investigator may also withdraw a subject from receiving the study product for any reason. 
Follow -up safety evaluations will be conducte d, if the subject agrees. If a subject withdraws or is 
withdrawn prior to completion of the study, the reason for this  decision must be recorded  in the 
case report forms . 
A subject may also be discontinued f rom participation in the study for any of the following 
reasons : 
• Request by the subject to terminate participation in the study  
• Inability to collect blood samples  or receive study product  due to poor venous access  or 
other reasons  
• Noncompliance, based on the opinion of the site PI  
• Loss to Follow -up 
• Request of primary care provider  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   40 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • At the request of the IRB, DMID, or FDA  
• Incarceration  
• Subject’s well -being, based on the o pinion of the site PI  
• SMC recommendation  
• Death  
• Additional information becomes available that makes further participation unsafe  
• Subject withdraws informed consent  
• Subject no longer meets eligibility criteria  
5.2.2 Subject Replacement  
Subjects who withdraw before  receiving study product  will be replaced. Up to 1  subject per 
cohort may withdraw after dosing but before Day 112 without being replaced.  Should more than 
1 subject from the same cohort withdraw from the study before  Day 112, they will be replaced . 
Subjects who received any amount of study product  will be encouraged to continue Follow -up 
(with subject's consent) for safety. Subjects withdra wing will be asked to complete the ET visit if 
they do not wish to be followed per protocol. Any decision to replace a subject who withdraws 
after receiving study product  will be documented in a note to file. Replacement subjects will 
receive the same trea tment as the subject being replaced.  The Statistical a nd Data Coordinating 
Center (SDCC ) must be contacted prior to enrolling any replacement subjects.  
If a subject fails to appear for a safety Follow -up asse ssment, extensive effort (ie, 3  documented 
conta ct attempts via phone calls, email etc., ) made on separate occasions and followed by a 
certified letter) will be made to locate or recall him or her or at least to determine his or her 
health status. These efforts will be documented in the subject's record s. 
If an AE or SAE has occurred, every effort will be made to undertake protocol -specified safety 
Follow -up procedures, and the subject will be encouraged to receive appropriate medical care 
until the symptoms of the AE resolve or the subject’s condition becomes stable. If a subject 
withdraws following dosing, analyses  for safety, PK, and immunogenicity  will be completed on 
blood samples already obtained . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   41 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 5.2.3 Study Termination  
If the study is prematurely terminated by the spon sor, any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure  
appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   42 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 STUDY PROCEDURES  
 Recruitment  
Subjects will be recruited and enrolled in this study using IRB -approved procedures and 
materials, such as a subject -recruitment database, websites, outreach events, and electronic or 
other media. Recruitment, medical Screening, and study procedures will b e performed separately 
at each site.  
This study will not include special classes of subjects ( eg, fetuses, neonates, prisoners, 
institutionalized individuals, or other vulnerable populations) for whom there are no known 
benefits in the Phase 1 trial.  
Parti cipation in this study will not routinely exclude women or minorities. Subjects will be 
recruited without regard to sex or race. Women of childbearing potential will be included but 
will undergo pregnancy testing and be required to use effective con tracept ion from 45 days 
before study product  administration until 150 days after study product  administration  (see 
inclusion criterion # 2). Also, female subjects will be asked to contact the site PI if  they become 
pregnant during the study . Male subjects will be asked to contact the site PI if their female 
partners become pregna nt during the study  (see inclusion criterion # 4). Recruitment and 
Screening of alternate subjects is permitted to facilitate study enrollment. Alternative individuals  
will be allowed to enroll in the study if the original subjects do not participate for any reason. If 
the alternative is not selected on the dosing day, he or she will receive remuneration for their 
time and inconvenience and may return to participate in future cohorts if they are within the 
Screening window and meet eligibility. If alternative subjects are not dosed in the cohort when 
they originally met eligibility, they may be rescreened. No study procedures will be completed 
until signed informed conse nt has been obtained.  
Subject inclusion and exclusion criteria must be assessed by a study clinician licensed to make 
medical diagnoses and listed on Form FDA  1572 as the site PI or sub-investigator . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   43 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 Screening  (Day -45 through Day -2) and Admission to Cli nical Site  
(Day -1) 
Each subject will undergo an eligibility screening. The following procedures will occur 
during Screening (Day -45 through Day -2): 
• Obtain signed informed consent and Health Insurance Portability and Accountability Act  
authorization.  
• Obtain a complete medical history, including assessment of concomitant medications , 
menstrual history (if applicable),  and history of alcoh ol or drug abuse in the last 
12 months.  
• Record demographics.  
• Record height and weight, calculate BMI  using NIH calculator 
(https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm ). Screening 
weight will be used to determine participant eligibility and Day -1 weight will be used for 
dose calculations.  
• Perform triplicate 12 -lead ECGs with 10 -second rhythm strips after subject  has been 
supine for at least 5  minutes (before blood collections and within a 15 -minute  period, 
separated by at least 1 minute ) and evaluate the rhythm to determine if any CS findings 
are present and confirm that the QTcF m eets the inclusion criteria.  
• Record vital signs (BP, heart rate , temperature, respiratory rate) after  ECGs and before 
blood collections.  
• Conduct complete physical examination.  
• Collect blood samples for:  
o Hematology  
o Chemistry  
o Coagulation panel  
o Viral serology  testing ( CHIKV , HIV, hepatitis C virus, hepatitis B surface 
antigen ) 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   44 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 o Serum β -hCG pregnancy test for women of childbearing potential  
o Serum follicle -stimulating hormone  only to confirm postmenopausal status  
o Estimated laboratory calculation of creatinine clearance  and glomerular filtration 
rate. 
• Collect a urine sample for:  
o Urinalysis dipstick  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein . Urinalysis will be repeated as described in the footnote 
section of Table  7-1 for menstruating females.  
o Urine drug screen  including cotinine . Subjects  should be notified by phone not to 
consume any poppy seeds within 24  hours before the screening urine test to avoid 
a false positive opioid test result.  
• Breathalyzer to test for presence of alcohol.  
• Record all prior/concomitant medica tions taken with in p revious 45 days of Screening.  
• Review childbearing potential and contraception (if applicable) . 
• Council on the avoidance of pregnancy.  
All subjects will be informed  of their eligibility and, if selected, will be asked to avoid extreme 
physical activity (for example: long distance running or biking, weight lifting, or playing contact 
sports ) from Screening until discharge from the clinic al site  on Day 4.  
All laboratory  testing for screening and safety monitoring will be performed at the clinical site’s 
clinical laboratory improvement amendments ( CLIA ) approved laboratories indicated on the 
Form FDA 1572 . 
A repeat of exclusionary safety assessments (ie, vital sign measur ements , ECGs, and clinical 
laboratory assessments)  is permitted  at Screening  and on Day -1 at the discretion of the PI . 
All subjects will arrive at the clinical site no later than the  day before study product  
administration (Day -1). If screening labo ratory tests occurred within 48  hours of admission, they 
do not have to be repeated except for the pregnancy test for females of childbearing potential and 
the breathalyzer  and urine drug screen for all subjects. If a subject meets eligibility criteria but  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   45 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 was not dosed, the subject can be reevaluated (rescreened) once for participation in the study.  If a 
subject is reevaluated  (rescreened)  within 3  months of serological testing ( CHIKV, HIV, 
hepatitis C virus , hepatitis B surface antigen), it will not be re peated. The subject’s history must 
be reviewed to ensure no new risk factors for hepatitis or HIV have occurred since the last 
serological testing.  
For detailed instructions of each assessment and procedure, refer to the Schedule of Events in 
Appendix A . 
The following procedures will occur upon admission to the clinical site (Day -1): 
• Confirm that the subject meets all study inclusion criteria and no exclusion criteria.  
• Obtain  weight  for dose calculations . 
• Obtain an interim medical history since Screening.  
• Confirm concomitant medication usage and review of birth control since Screening.  
• Admit subject.  
• Record vital signs before blood collections.  
• Conduct complete  physical examination.  
• Collect blood specimen for:  
o Hematology  
o Chemistry  
o Coagulation panel  
o Serum β -hCG  pregnancy test for women of childbearing potential  
o Renal injury biomarker serum cystatin -C. 
• Collect a urine specimen for:  
o Urinalysis  dipstick  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein  (see Table  7-1 for a complete list of clinical laboratory 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   46 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating females.  
o Urine drug screen  
o Cotinine screen . 
• Perform breathalyzer test for presence of alcohol.  
• Randomization  
 Confinement and Infusion (Day 1 through Day 4)  
For detailed instructions of each assessment and procedure, refer to the Schedule of Events in 
Appendix A . 
The following procedures will occur prior t o dosing on the day of study product  
administration  (Day 1) : 
• Review medical history . 
• IV catheter insertion for administration of study product . Straight stick or IV catheter 
insertion for collection of blood samples.  If catheters are utilized , they will be placed in 
different arms.  
• Perform triplicate 12 -lead ECGs with 10 -second rhythm strips after subject  has been 
supine for at least 5  minutes (before blood collections and within a 60-minute period  
prior to dosing , separated by at least 1  minute). The EC G will be obtained within a 
60-minute period  prior to dosing  and within approximately 15 minutes after dosing is 
complete.  Continuous remote telemetry monitoring will be conducted from 30 minutes 
prior to study product administration to approximately 4  hours post dose.  
• Record vital signs before blood collections.  Vital signs will be check ed within a 
60-minute period  prior to dosing and approximately every 15  minutes during the 
infusion.  
• Record concomitant medications  and review of birth control . 
• Conduct symptom -directed physical examination as needed.  
• Obtain blood for PK and immunogenicity  (ie, ADA)  analyses (see Section  7.2.2.1 ). 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   47 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Collect blood specimen  for: 
o Hypersensitivity panel . 
The following procedures will occur during  product  administration:  
• Administer study drug  product . 
• Collect  vital signs  every 15  minutes  (±5 minutes)  during the infusion.  
• Direct observation by RN  or designated clinical staff  for the duration  of the infusion . 
• Symptom -directed physical examination for AE or SAE , signs and symptoms of infusion 
reaction, or at the discretion of the inve stigator  
o Collect blood specimen s for hypersensitivity panels if infusion reaction occurs . 
Should an anaphylactic or anaphylactoid -type reaction occur, the subject will be 
treated using the standard protocol at the clinical site. Infusion -related AEs and 
suspected hypersensitivity reactions will be documented including clinical 
presentation and severity (based on grading scales in Appendix B  and NCI 
CTCAE, Version 5.0 – November  2017 ) of the event.  
o Symptom -directed treatment at direction of qualified investigator or sub -
investigator . 
The following procedures will occur following product administration (end of infusion):  
• Obtain blood for PK analysis (s ee Section  7.2.2 ). 
• After the infusion, vital signs  will be taken at the following time points: 1, 2, 4, and 6  
hours with an acceptable window of ±5  minutes  for each time point.  
• Symptom -directed physical examination for AE, signs and symptoms of infusion 
reaction, or at the discretion of the investigator . 
The following procedures will occur on the days following study product  administration  
(Day 2 and Day 3) : 
• Record vital signs before blood collections.  
• Conduct symptom  -directed physical examination as needed.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   48 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Collect blood specimen  each day  for: 
o Hematology  
o Chemistry  
o Coagulation panel  
o Renal injury biomarker  serum cystatin -C. 
• Collect a urine specimen  each day  for: 
o Urinalysis  dipstick  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein (see Table  7-1 for a complete list of clinical laboratory 
evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating  females.  
• Assess, identify, and record any AEs or SAEs after first dose of study product . 
• Record concomitant medications.  
• Obtain blood for PK analys is (see Section  7.2.2.1 ). 
The following procedures will occur on the day of discharge from the clinical site  (Day 4) : 
• Perform triplicate  12-lead ECG with 10 -second rhythm strips after subject  has been 
supine for at l east 5  minutes (before blood collections and within a 15 -minute period, 
separated by at least 1  minute) . 
• Record vital signs before blood collections.  
• Conduct complete physical examination . 
• Collect blood specimen  for: 
o Hematology  
o Chemistry  
o Coagulation panel  
o Renal injury biomarker  serum cystatin -C. 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   49 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Collect a urine specimen  for: 
o Urinalysis  dipstick  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein (see Table  7-1 for a complete list of clinical laboratory 
evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating females.  
• Review laboratory data (including all Day 4 safety labs  with the exception of cystatin -C), 
vital signs, and a ssess, identify, and record any AEs or SAEs after study product  
administration . 
• Record concomitant medications  and review of birth control . 
• Council on the avoidance of vaccines  (with exception of influenza  and COVID -19 
vaccine s after Day 56 per Section  5.1.2 ). 
• Obtain blood for PK analys is (see Section  7.2.2.1 ). 
• Counsel on the avoidance of pregnancy  (all participants ) and prohibited 
medications/substances , including lifestyle restrictions (eg, no tobacco use  or vaping , no 
excessive caffeine intake  [> 400 mg of caffeine per day ], and to  avoid extreme physical 
activity  72 hours prior to Follow -up visits ). 
• Discharge from the clinical site following review of safety labs, ECG, and other 
assessments and counsel on reporting changes in well -being between visits . 
 Outpatient  Study Visits   
6.4.1 Follow -up (Day 7 ±1, 14 ±2, 28 ±4, 56 ±4, 84 ±7, 112  ±7) 
• Confirm concomitant medication usage and review of birth control  since last visit . 
• Record vital signs before blood collections.  
• Conduct symptom -directed  physical examination  as needed . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   50 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Collect blood specimen for:  
o Hematology  
o Chemistry  
o Coagulation panel  
o Rena l injury biomarker  serum cystatin -C.  
• Collect a urine specimen for:  
o Urine β -hCG pregnancy test for all women  of childbearing potential  (see 
Schedule of Events in Appendix A  for timing ) 
o Urinalysis  dipstick  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein  (see Table  7-1 for a complete list of clinical laboratory 
evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating females.  
• Obtain blood for PK and immunogenicity  analyses  (see Section  7.2.2.1 ). 
• Assess, identify, and record any AE s or SAEs after  the administration of  study product . 
• Counsel on the avoidance of pregnancy  (males and females)  and prohibited 
medications/substances , including lifestyle restrictions (eg, no tobacco use  or vaping , no 
excessive caffeine intake  [> 400 mg/day] , and to avoid extreme physical activity  72 hours 
prior to Follow -up visits ). 
• Counsel on the avoidance of vaccines at Follow -up visits through Day 56 . 
6.4.2 Final Study Visit  (Day 1 50 ±7) 
• Confirm concomitant  medication usage  and review of birth control  since last visit . 
• Record vital signs before blood collections . 
• Conduct complete  physical examination.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   51 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Perform triplicate 12 -lead ECGs with 10 -second rhythm strips after subject  has been 
supine for at least 5  minutes (before blood collections and within a 15 -minute period, 
separated by at least 1  minute).  
• Collect blood specimen for:  
o Hematology  
o Chemistry  
o Coagulation panel  
o Renal injury biomarker  serum cystatin -C.  
• Collect a urine specimen for:  
o Urinalysis  dipstick  
o Urine β -hCG pregnancy test for all women  of childbearing potential  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein  (see Table  7-1 for a complete list of clinical laboratory 
evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating females.  
• Obtain blood for PK analyses and immunogenicity  (see Sectio n 7.2.2.1 ). 
• Assess, identify, and record any AEs or SAEs after the administration  of study product . 
6.4.3 Early Termination Visit  (if needed)  
• Confirm concomitant medication usage and review of birth control  since last visit . 
• Record vital signs before blood collections.  
• Conduct complete physical examination.  
• Perform triplicate 12 -lead ECGs with 10 -second rhythm strips after subject  has been 
supine for at least 5  minutes (before blood collections and within a 15 -minute period, 
separated by at least 1  minute).  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   52 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Collect blood specimen for:  
o Hematology  
o Chemistry  
o Coagulation panel  
o Renal injury biomarker  serum cystatin -C 
o Hypersensitivity panel (if suspected infusion reaction) . 
• Collect a urine specimen for:  
o Urinalysis  dipstick  
o Urine β -hCG pregnancy test for all women  of childbearing potential  
o Urine with reflex microscopy if dipstick is positive for red blood cells, white 
blood cells, or protein  (see Table  7-1 for a complete list of clinical laboratory 
evaluations ). Urinalysis will be repeated as described in the footnote section of 
Table  7-1 for menstruating females.  
• Obtain blood for PK and immunogenicity  analyses  (see Section  7.2.2.1 ). 
• Assess, identify, and record any AEs or SAEs after the administration  of study product . 
• Counsel on the avoidance of pregnancy  (males and females)  and prohibited 
medications/substances  until 150 days has elapsed from receipt of study product . 
• If subject is unwilling or unable to have an in person ET visit, study team will attempt to 
contact subject via telephone to review medical history, concomitant medications, and 
AEs. 
 Unscheduled Study Vis its 
A subject may return to the clinic al site  for an unscheduled visit at any time  for specimen 
collection, AE Follow -up, re -screening, or at the discretion of the PI . The following procedures 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   53 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 will be performed at the discretion of the PI . Additional procedures may be performed, as 
needed, at the discretion of the PI.  
• Record vital signs before blood  collection.  
• Conduct a symptom -directed physical exam.  
• Assess, identify, and record any AEs or SAEs  after the administration of study product . 
• Record all prior/concomitant medications  and review of birth control . 
• Obtain an interim medical history.  
 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice 
(GCP ), or protocol -specific MOP re quirements . The noncompliance may be either on the part of 
the subject, the site PI, or the site personnel. As a result of deviations, corrective actions are to be 
developed by the site and implemented promptly.  
These practices are consistent with International C ouncil  for Harmonisation  (ICH) E6: 
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3  
5.1 Quality Assurance and Quality Control, Section 5.1.1  
5.20 Noncompliance, Sections 5.20.1, and 5.20.2  
It is the responsibility of the site PI and other study personnel to use continuous vigilance to 
identify and report deviations . All deviations must be promptly reported to DMID per the SDCC 
protocol deviation reporting procedures.  
All protocol deviations,  as defined above, must be addressed in study subject data collection 
forms. A completed copy of the DMID Protocol Deviation Form must be maintained in the 
Regulatory File, as well as in the subject's chart. Protocol deviations must be sent to the IRB/IEC 
of record per their guidelines. The site PI and other study personnel are responsible for knowing 
and adhering to IRB requirements.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   54 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 DESCRIPTION OF CLINICAL AND LABORATORY 
EV ALUATIONS  
The Schedule of Events  is presented in Appendix A . For timing of and instructions for 
performing the laboratory assessments, see the Schedule of Events  and the Laboratory Manual; 
for a list of specific laboratory tests to be performed, se e Table  7-1. 
 Clinical Evaluations  
The following clinical evaluations will be completed during the study : 
• Complete medical history: includes current diagnoses, past diagnoses, surgical history, 
current med ications, date of last menses for women, current contraceptive methods, 
smoking status, and allergies.  
• Interim medical history: includes medical history that occurred between previo us 
encounter and current visit.  
• Concomitant medications: includes current m edicati ons, medications in the past  45 days 
prior to dosing (including OTC, herbal s, vaccines,  prescription, supplements, vitamins 
and illicit  substances).  
• Height  at screening . Weight and BMI at screening and Day -1. Screening weight will be 
used to determ ine participant eligibility and Day -1 weight will be used for dose 
calculations.  
• Vital signs : temperature, heart rate , BP, and respiratory rate  within normal limits will be 
assessed once at each time point per the Schedule of Events. Subjects will rest supine for 
at least 5  minutes prior to vital signs measurement. If a physiologic parameter, eg, a vital 
sign, is outside of the protocol -specified  range, then the measurement may be repeated 
once if, in the judgment of the site PI, the abnormality is the result of an acute, short -
term, rapidly reversible condition (eg, stress, anxiet y, or “white coat syndrome”). 
A physiologic parameter may also be r epeated if there is a technical problem with the 
measurement caused by a malfunctioning or inap propriate measuring device 
(eg, inappropriately sized BP cuff).  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   55 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Once study product administration has started , any AEs involving BP and HR, 
3 measurements on the  same arm  used for  previous vital sign measurements  at least 
5 minutes apart  with concordant results will be taken to confirm.  
• Complete physical examination *: general appearance, head, ears, external examination of 
eyes,  nose, throat, dentition, thyroid, c hest (heart, lungs), abdomen, skin, neurological, 
extremities, back, neck, musculoskeletal, and lymph nodes.  
• Symptom -directed physical examination * (performed only if a participant endorses  a 
symptom  and at the discretion of the PI ). The symptom -directed physical exam will be 
limited to  one o r more o f the body systems as described  under “complete physical 
examination”, localized to the pa rticipan t’s complaint(s)  at the discretion of the 
examining prov ider. 
*All physical examinations will be performed by qualified investigator or 
sub-investigator listed on the  Form  FDA 1572.  
• 12-lead ECG: subjects will be aske d to rest supine for at least 5  minutes prior to ECG.  
o Triplicate ECGs with 10 -second rhythm stri ps will be obtained within a 
60-minute period  prior to dosing and within approximately 15  minutes after 
dosing is complete , separated by at least 1  minute.  
o Single, standard 12 -lead safety ECGs will also be obtained.  
o All ECG recordings will be taken before obtaining any blood sample.  
o Significant changes are defined as the following:  
▪ Any significant change in rate or rhythm as determined by the site PI  
▪ QTcF interval of greater than  450 ms ec (male) or greater than  470 msec 
(female)  
▪ Increase from the QTcF  baseline (defined as mean of pre -dose 
measurements)  greater than  50 ms ec until the change resolves . 
If any of these changes are observed, triplicate ECG tracings, approximately 
2 minutes apart, should be recorded and repeated hourly until cessation of the  
abnormality.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   56 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 o Reader will sign and date the safety ECGs and provide a global interpretation 
using the following categories:  
▪ Normal  
▪ Abnormal —not clinically significant (N CS) 
▪ Abnormal —CS 
o Clinically significant  ECG findings with new onset (or change in severi ty or 
frequency) any time after the administration of  study product  will be recorded as 
AEs. Clinical significance of ECG findings will be determined by the site PI 
based on his/her overall interpretation of data. Original ECG tracings will be 
retained as source documentation in the subject's records at the clinical site . 
o During the study, from 30  minutes before the administration of study product  
until approximately 4 hours post dose , continuous 12 -lead ECG remote telemetry 
monitoring will be conducted to assess for acute changes. If a CS change occurs, 
the monitoring will be continued until it has resolved and it is deemed safe to 
discontinue monitoring by the site PI or designee.  
7.1.1 Assessment of Concomitant Medications/Treatments  Other Than Study Product  
All OTC  medications or herbal, nutritional, and dietary supplements within 7 days and selected 
prescription medications  within 14 days  before study product  administration  are prohibited per 
exclusion criteria . Influenza vaccine and COVID -19 vaccine  are permitted if given more than 
45 days before study product administration or after Day 56.  No other vaccines are permitted 
within 45 days of study product administration or duration of study. Concurrent therapy with any 
prescription or OTC medication (exce pt for acetaminophen or  NSAID  in the case of necessary 
treatment of AEs) during the course of the protocol afte r randomization should be reviewed by 
the site PI before study product  infusion , unless appropriate medical care necessitates that 
therapy should begin before the site PI can be consulted . Nonprescription systemic drugs may be 
used after Day 28 while prescription drugs (excluding contraceptives in females) may be used 
after Day 56.  
Administration of any medications, therapies, or vaccines will be recorded on the appropriate 
data collection  form. Concomitant medications will include all current medications and 
medications taken in the 45 days before  study treatment administration  throu gh the last study 
visit.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   57 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 7.1.2 Assessment of Subject Compliance with Study Intervention/Investigational 
Product/Investigational Device  
Subjects will be directly observed at the time of dosing by a blinded member of the clinical 
research team who is trained and delegated  to administer the study product. Treatment 
compliance will be documented in the electronic case report form (e CRF) by recording the date, 
start time, stop time, and whether the dose of study product  was completely infused.  
 Laboratory Evaluations  
Refer to Table  7-1 for a complete list of clinical laboratory evaluations  and to the Schedule of 
Events  (Appendix A ) for corresponding time points.  
7.2.1 Clinical Laboratory Evaluations  
Laboratory reference ranges for the site that screened and enrolled subjects prior  to Protocol 
Version 11.0 are provided in Appendix C  and Appendix D . Laboratory reference ranges for sites 
that screen and enroll subje cts with Protocol Version 11.0 are provided in the MOP. Each site 
will maintain a list of the normal ranges and units of measurement for the laboratory parameters 
to be determined during this study, and the data and certification number of the laboratory. If the 
normal ranges change during the course of the study, the site investigator must update this list 
with the new ranges and effective dates. The normal laboratory reference ranges will also be 
retained in the regulatory binder at each site.  
Table  7-1: Clinical Laboratory Evaluations  
Hematology  Chemistry  Urinalysis  
Hemoglobin+ 
Platelet count*  
White blood cell count* 
Hematocrit  
Red blood cell count  
Basophil count  
Eosinophil count  
Lymphocyte count  
Monocyte count  
Neutrophil count  Alanine  aminotransferase++ 
Aspartate aminotransferase++ 
Creatinine* ** 
Bilirubin, total*  
Sodium ** 
Potassium ** 
Bicarbonate ** 
Glucose  (random at Screening, 
otherwise fasting  for a min imum  of 
2 hours) 
Blood urea nitrogen  Protein  
Blood ^ 
Ketones  
Glucose  
Bilirubin  
Nitrites  
Urobilinogen  
White blood cells  
Protein -to-creatinine ratio^^  
Note:  If any abnormal value is 
observed on the urine dipstick test, 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   58 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Table  7-1: Clinical Laboratory Evaluations  
Hematology  Chemistry  Urinalysis  
Pregnancy test (serum  or urine ) 
Calcium  
Alkaline phosphatase  
Bilirubin, direct  
Albumin  
Protein, total  
Estimated glomerular filtration 
rate*** 
Follicle stimulating hormone  
Cystatin -C 
Creatinine Clearance  the sample should be further 
analyzed with urine chemistry and 
microscopy. ^^^ 
Urinalysis will be repeated as 
necessary for menstruating females.  
Coagulation  Drugs of Abuse (Urine) and 
Alcohol Testing ** Serology Screen  
Activated partial thromboplastin 
time 
Prothrombin time  
International normalized ratio  Cannabinoids  
Amphetamines  
Barbiturates  
Cocaine  
Opiates  including Methadone  
Benzodiazepines  
Phencyclidine  
Cotinine  
Breathalyzer (alcohol)  Hepatitis B surface antigen  
Hepatitis C antibody  
Human immunodeficiency virus 
1 and 2 antibod y with antigen  
CHIKV  IgG and IgM antibody  
Any lab value may be repeated if felt erroneous due to laboratory error.  
*Values outside the acceptable limits at Screening only are exclusionary  with exception of total bilirubin for which 
ULN  values will be allowed at Screening and Day -1/Baseline provided t he AST and ALT are within normal limits .  
**Values outside the acceptable limits at Screening and Day -1 are exclusionary.  
***Values  for creatinine results that Grade 1 or higher at Screening and Day -1 prior to Protocol Version 11.0 were 
exclusionary. With Protocol Version 11.0, creatinine is not an exclusionary criteri on, instead subjects should have a 
calculated  eGFR using the CKD -EPI of ≥ 90 mL/min/1.73m2 to be enrolled in the study.  
+For hemoglobin; a lower limit within 0.5 g/dL of the LLN  is allowable at Screening.  
++For AST/ALT; results are  exclusionary if Screening results are 1.5 × ULN or if assessed as CS by the site PI. 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   59 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 ^Urine abnormalities in menstruating females will trigger repeat urinalysis within the next 14 days, either at a 
scheduled study visit or via unscheduled study visit following cessation of menses. Urine abnormalities in females 
attributable to menstruation  will not be considered AEs.  
^^Urine p rotein -to-creatinine ratio will be calculated  at Screening and Day -1. 
^^^Repeat urine collection if cellular elements in the microscopic exam indicate the participant did not success fully 
follow clean catch instructions.  
7.2.2 Research  Assays  
• SAR440894 plasma concentrations will be determined by using a validated 
enzyme -linked immunosorbent assay.  
• ADA in K3EDTA plasma will be assessed by using validated bridging 
electrochemiluminescence assays for Screening, confir mation and titration.  
• Plasma PK samples should be collected in tubes that contain  K3EDTA  anticoagulant  
using  venipuncture . For PK blood samples collected on Day 1, the arm other than used 
for drug infusion  will be used . 
o For blood sample collection, there wi ll be an acceptable window of ± 10 minutes 
in the first 8  hours after dosing and ±30  minutes between 9  and 72 hours . PK 
samples at Follow -up visits will be collected during the designated Follow -up 
window. The "end of infusion" sample sh ould be obtained within 5  minutes of the 
end of the infusion. Actual times of blood sample acquisit ion will be carefully 
recorded.  
o PK samples collections will be performed at the following time points : Baseline 
pre-infusion  (60 to 0 min utes prior to start of infusion) , at the completion of the 
infusion, and at  (relative to the end of the infusion) : 1, 4, 8, 12, 24, 48, and 
72 hours, and on  Day 7 ±1, Day 14  ±2, Day 28  ±4, Day 56±4, Day 84 ±7, 
Day 112±7, Day 150 ±7, and ET (if needed) . 
o PK sampl es will be analyzed by Aptuit (Verona) Srl.  
• Immunogenicity samples for ADAs will be analyzed by Aptuit (Verona) Srl .  
o Plasma samples for ADA measurements will be collected pre-infusion  (60 to 
0 minutes prior to start of infusion) , Day 56  ±4, Day 112  ±7, Day 150 ±7, and ET. 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   60 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 7.2.2.1  Blood Volume  
The total amount of blood collected from each subject over the duration of the study, including 
any extra assessments that may be required, will not exceed 450 mL . 
7.2.2.2  Laboratory Specimen Preparation, Handling, and Storage  
Instructions related to handling of safety laboratory samples and PK blood samples, including 
how to process blood and prepare aliquots, sample storage, and disposition are provided in the 
MOP.  
A hypersensitivity sample will be collected on all subjects at  baseline  (pre-dose on Day 1)  and 
stored frozen  on site . If a subject experiences anaphylaxis or an anaphylactoid event  related to 
the infusion, three additional samples will be collected during onset, 2 or more hours after onset 
and after resolution of symptoms. Samples will only be analyzed in the event of a 
hypersensitivity reaction. Hypersensitivity samples will be collected, processed and stored frozen 
on site and sent to the testing lab if needed. Baseline samples will be discarded at the end of the 
study if there are no hypersensitivity events.  Prior to discarding samples, DMID or an authorized 
representative must notify the site and approve sample destruction.  
Details on the collection, storage, testing, and disposition of used and un used hypersensitivity 
samples will be provided in the protocol -specific MOP.  
7.2.2.3  Laboratory Specimen Ship ping  
Specimen shipment will occur at intervals during this study following all applicable International 
Air Transport Association requirements and accordin g to the specifics for storage temperature 
and documentation as detailed in the central (clinical) laboratory manual and MOP as 
appropriate.  
Further instructions for specimen shipment are included in the MOP, as appropriate.  
Clinical laboratory assessments  will be performed by the clinical site CLIA approved 
laboratories indicated on the Form FDA 1572 . Plasm a samples for PK analyses  and ADA  will be 
shipped on dry ice to Fisher BioServices before sending them to Aptuit (Verona) Srl. 
Fisher BioServices  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Telephone: 240 -477-1350  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   61 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Email: DMID.CMS@ThermoFisher.com  
Fax: 240 -477-1360  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   62 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 ASSESSMENT OF SAFETY  
 Assessing and Recording  Safety Parameters  
Safety will be assessed through the evaluation of AEs, vital signs, ECGs, and conventional 
clinical laboratory data (clinical chemistry panels and hematology, coagulation, immunogenicity, 
and urinalysis evaluations), according to the Schedule of Events  (Appendix A ). 
8.1.1 Adverse Events  
International Council  for Harmonisation  E6 defines an AE as any untoward medical occurrence 
in a patient or clinical investigation subject administered a pharmaceutical product regardless of 
its causal relationship to the study treatment. The FDA  defines an AE as any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered drug related.  
A treatment -emergent AE (TEAE) is defined as an AE that occurs during or after the first study 
product  infusion and up through the final visit. Only TEAEs  will be documented as AEs in this 
study. Adverse events that occur between the time of consent  and administration of study 
product  will be recorded in the medical history . 
An AE can therefore be any unfavorable and unintended sign (including a  CS abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product. The occurrence of an AE may come to the attention of study personnel 
during study visits and interviews of a study recipient presenting for medical care, or upon 
review by a study monitor.  
All AEs will be captured on the appropriate  data collection form and eCRF.  Information to be 
collected for AEs includes event description, date of onset, assessment of severity , relationship to 
study product and alternate etiology  (assessed only by those with the training and authority to 
make a di agnosis  and listed on the Form  FDA  1572 as  an investigator), date of resolution , 
seriousness , and outcome. Adverse events  occurring during the study  collection and reporting 
period will  be documented appropriately regardless of relationship. Adverse events  will be 
followed through  resolution  or stabilization, as indicated by an investigator . 
Any medical condition that is present at the time that the subjec t is screened will be considered  
as baseline and not reported as an AE. However, if the severity of any pre -existing medical 
condition increases , it should be recorded as an AE.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   63 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Medically -indicated  laboratory tests (emergency or unscheduled tests) should be conducted at 
the local site laboratory.  
The site investigator should employ the best medical judgment in determining how to manage 
AEs and SAEs.  
8.1.1.1  Adverse Events Grading  
All AEs  (laboratory and cli nical symptoms)  will be graded  by the licensed study physicians on 
Form FDA 1572 for severity and assessed for relationship to study product . The start and stop 
date of each reported AE will be recorded on the appropriate data collection form and eCRF.  
Severity of Event:  
Subjects who screened and enrolled prior to Protocol Version 11.0, AEs  will be assessed by the 
investigator using a protocol -defined grading system  (see T oxicity Table, Appendix B ). For 
even ts not included in the protocol -defined grading system, the following guidelines will be used 
to determine  severity:  
• Mild (Grade 1) : Events that are usually transient and may require  only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the subject’s 
usual activities  of daily  living . 
• Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic intervention . The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant.  
• Severe (Grade 3) : Events interrupt usual activities of daily living, or significant ly affect 
clinical status, may require intensive therapeutic intervention , or death related to an AE . 
Severe events are usually incapacitating.  
Subjects who screen and enroll with Protocol Version 11.0,  AEs will be assessed by the 
investigator using the  NCI CTCAE , Version 5.0 – November  2017.4 For even ts not included in 
the NCI CTCAE grading system, the following guidelines will be used to determine  severity : 
• Grade 1 ( Mild): Asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   64 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • Grade 2 (Moderate): Minimal, local, or noninvasive intervention indicated; limits 
age-appropriate instrumental activities of daily living (eg, prepa ring meals, shopping for 
groceries or clothes, using the telephone, managing money).  
• Grade 3 (Severe): Medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limits self -care 
activities of daily living (eg, bathing, dressing and undressing, feeding self, using the 
toilet, taking medications, and not bedridden).  
• Grade 4 (Life  threatening): Urgent intervention indicated.  
• Grade 5 (Death).  
Relationship to Study Product: The assessment of the AE’s relationship  to study product will 
be done by the licensed study physician indicated on the Form FDA 1572 and the assessment 
will be part of the documentation process . Whether the AE is related or n ot is not a factor in 
determining what is or is not reported in this study . If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported.  
In a clinical study , the study product must always be suspect. The relationship t o study product 
will be assessed for AEs using the terms  “Related ” and “Not Related ”. 
• An investigator should use good clinical judgment. If the event is believed to be unrelated 
to study product , an alternative  plausible  explanation must be provided.  Otherwise, AEs 
will be considered related to the study product.  
8.1.2 Serious Adverse Events  
An AE or suspected adverse reaction is considered  an SAE if it occurs between the time of 
receiving study medication and the final study visit, and  in the view of either the  site PI or 
sponsor;  it results in any of the following outco mes:  
• Death,  
• A life-threatening* AE, 
• Inpatient hospitalization or prolongati on of existing hospitalization,  
• A persistent or significant incapacity or substantia l disruption of the ability to co nduct 
normal life functions, or  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   65 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 • A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical 
judgment , they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring inte nsive treatment in an 
emergency room or at home, blood dyscrasias , or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.  
*Life-threatening AE: An AE is considered “life -threatening” if, in the view of either the site PI 
or sponsor, its occurrence places the patient or subject at immediate risk of death. It does not 
include an AE that, had it occurred in a more severe form, might have caused death.  
SAEs will be:  
• Assessed for severity and relation ship to study product and alternate etiology  (if not 
related to study product) by a licensed study physician listed on the Form  FDA  1572 or 
by the Institution as the site PI or sub-investigator . 
• Recorded on the appropriate SAE data collection form and eCRF . 
• Followed through resolution  by a licensed study physician (for IND studies, a physician 
listed on the Form  FDA  1572 as the site PI or sub-investigator ). 
• Reviewed and evaluated by DMID  or SMC (periodic review unless related), and the 
IRB/IEC . 
8.1.3.  Suspected Unexpected Serious Adverse Reactions (SUSAR)  
A SUSAR is any SAE where a causal relationship with the study product is at least reasonably 
possible but is not listed in the IB, Package Insert, and/or Summ ary of Product Characteristics.  
The IND Sponsor is responsible for making the determination of which SAEs are “serious and 
unexpected suspected adverse reactions” (SUSARs) as defined in 21 CFR 312.32.  
• Suspected Adverse Reaction  means any AE for which there is a reasonable possibility 
that the drug  caused the AE.  
• Unexpected Adverse Event  means an AE that is not listed at the specificity or severity 
that has been observed.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   66 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 All SUSARs (as determined by the IND Sponsor) will be reported to the FDA as IND Safety 
Reports per 21 CFR 312.32 as soon as po ssible but not exceeding 7 calendar days for unexpected 
fatal or life -threatening events, and not exceeding 15 calendar days for other qualifying events. 
IND Safety Reports will also be provided to the IRB.  
8.1.4 Unanticipated Problem  
An Unanticipated Problem ( UP) is defined as any incident, experience, or outcome that meets all 
the following criteria:  
• Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB approved research 
protocol and informed consent document; and (b) the characteristics of the subject 
population being studied; and  
• Related or possibly related to participation in the research (possibly related means there is 
a reasonable possibility that t he incident, experience, or outcome may have been caused 
by the procedures involved in the research); and  
• Suggests that the research places subjects, or others (which may include research staff, 
family members or other individuals not directly participatin g in the research) at a greater 
risk of harm (including physical, psychological, economic, or social harm) related to the 
research than was previously known or expected.  
• A UP must be reported within 7 calendar days of an investigator becoming aware of the 
actual or suspected UP.  
 Specification of Safety Parameters  
Safety will be assessed by the frequency and severity  of AEs and SAEs ; the incidence and 
maximum intensity of AEs and SAEs, vital sign measurements, ECG findings, and clinically 
important chang es in clinical laboratory values , defined as a change to a higher grade relative to 
baseline . 
AEs and SAEs will be addressed as they are reported or identified by a staff member. Safety 
laboratory reports are reviewed as available, generally within 24 hour s of sample collection . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   67 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 8.2.1 Solicited Events  
Solicited events are AEs that are common and known to occur following administration of study 
product.  There are no solicited events for this study . 
8.2.2 Unsolicited Events  
Unsolicited events are any other AEs that occur  following infusion  of study product.  
 Reporting Procedures  
8.3.1 Reporting Serious Adverse Events  
Serious AEs will be followed until resolution even i f this extends beyond the study  reporting 
period. Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectati on that it will remain chronic.  
Any AE that meets a protocol -defined serious criterion must be s ubmitted immediately 
(within 24  hours of site awareness) on a  DMID  SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US) 
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
In addition to the SAE form, select SAE data fields must also be entered into the SDCC system . 
Please see the protocol -specific MOP for details regarding this pro cedure.  
Other supporting documentation of the event may be requested by the DMID Pharmacovigil ance 
Group and should b e provided as soon as possible.  
The site will send a copy of the SAE report(s) when they are provided to the  DMID 
Pharmacovigilance Group. The DMID Medical Monitor and DMID Clinical Project Manager 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   68 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 will be notified of the SAE by the  DMID Pharmacovigilance Group. The DMID Medical 
Monitor will review and assess the SAE for regulatory reporting and potential impact on study 
subject safety and protocol conduct.  
At any time after completion of the study, if the site PI or appropriate sub -investigator becomes 
aware of an SAE that is suspected to be related to study product, the site PI or appropriate sub -
investigator will report the event to the DMID Pharmacovigilance Group.  
An Independent Safety Monitor (ISM) is not required for this study . 
8.3.2 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the site PI or appropriate sub -investigator, DMID, as the IND 
Sponsor, will report any suspected unexpected SAE . DMID will report an AE as a suspected 
unexpec ted AE only if there is evidence to suggest a causal relationship between the study 
intervention and the AE. DMID will submit an IND safety report to the FDA and will notify all 
participating site PIs (ie, all PIs to whom the sponsor is providing drug unde r its IND[s]  or under 
any PI’s IND[s]  of potential serious risks from clinical studies or any other source, as soon as 
possible ). DMID will report to the FDA any unexpected fatal or life -threatening suspected 
adverse reaction as soon as possib le, but in no  case later than 7  calendar days after the sponsor’s 
initial receipt of the information. If the event is not fatal or life -threatening the IND safety report 
will be submitted within  15 calendar days after the sponsor determines that the information 
qualifies for reporting as specified in 21 CFR Part 312.32. Relevant follow -up information to an 
IND safety report will be submitted as soon as the information is available. Upon request from 
the FDA, DMID will submit to the FDA any additional data or information that the agency 
deems necessary, as soon as possibl e, but in no case later than 15  calendar day s after receiving 
the request.  
All SAEs designated as “not related” to study product(s), will be reported to the FDA at least 
annually in a s ummary format.  
8.3.3 Reporting of Pregnancy  
Females of childbearing potential are excluded from this study unless they con sent to adequate 
contraception.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   69 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Female subjects , and female partners of male subjects,  must be instructed to inform the 
investigator immedia tely if they become pregnant during the study. In the event of a confirmed 
pregnancy  or positive pregnancy test , the following actions should be taken:  
• Pregnancy should  be reported to Emmes within 24  hours of notification, using the 
applicable pregnancy re port form.  
• Investigator should counsel the subject regarding the possible effects of prior 
SAR440894  exposure on the fetus and the need to inform the study site of the outcome of 
the pregnancy.  
• Subject should be followed , if possible, until th e immediate p ostnatal period (6  weeks) or 
until termination  or loss  of the pregnancy. The outcome should be reported to the 
Medical Monitor using the Pregnancy Outcome or Abnormal Pregnancy Outcome form.  
Pregnancy is not an AE itself. However, any pregnancy complicatio n or elective termination of a 
pregnancy for medical reasons will be recorded as an AE or SAE. A spontaneous abortion is 
always considered an SAE and will be reported as described in the AE and SAE sections. 
Furthermore, any SAE occurring as an adverse pre gnancy outcome post -study must be reported 
to the sponsor/DMID.  
 Type and Duration of Follow -up of Subjects After Adverse Events  
AEs and SAEs  will be followed through resolution or stabilization, as indicated by an 
investigator . 
Resolution of an AE is defin ed as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
 Procedures to be Followed in the Event of Abnormal Laboratory 
Test Values or Abnormal Clinical Findings  
The site principal investigator or sub -investigator is responsible for recording all AE/SAEs that 
are observed or reported during this trial, regardless of the relationship to study product . 
AE/SAEs, abnormal CS laboratory test values, or abnormal clinical  findings will be collected, 
assessed, documented, and followed appropriately . Subjects who screened and enrolled prior to 
Protocol Version 11.0 , grading of the ECG AEs will be based on the  Appendix B  toxicity table  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   70 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 and g rading of the laboratory and vital signs AEs will be based on the  Appendix C  and Appendix 
D. Subjects who screen and enroll with Protocol Version 11.0, toxicity will be assessed with the 
NCI CTCAE, Version 5.0 – November  2017 .4 
Isolated l aboratory test abnormalities should not be recorded as AEs or SAEs ; eg, if the 
laboratory abnormality is part of a clinical condition or syndrome, it should be recorded as the 
syndrome or diagnosis rather than as the individual  laboratory abnormality.  In addition, CS 
laboratory abnormalities or other abnormal test assessments (e g, ECGs) that are associated with 
signs or symptoms must be recorded as AEs or SAEs if they meet the definition of an AE (or 
SAE) as described in Section  8.1. Clinically significant l aboratory test abnormalities are 
documented on the laboratory form and not recorded as a  separate AE eCRF but the  relationship, 
clinical significance and grade are not ed on the laboratory screen.  
The site is utilizing standard panels for this protocol therefore if there are laboratory parameters 
not solicited in this protocol but are part of a standard panel that are abnormal and CS  as 
determined by the site PI then the  abnormal parameter will be reported on the AE eCRF.  
 Halting Rules  
The stopping rules outlined below will be used to evaluate whether it is safe to proceed with dose 
escalation or whether the study should be suspended  for further safety evaluation.  If any halting 
criteria are met, enrollment and dosing for subjects will be suspended at all sites until the event is 
assessed by the SMC.  
The SRC may be convened to provide an option for a rapid review of available safety data 
collected following the sentinel su bjects in each group. Otherwise,  confirmation by the site PI 
that the sentinel subjects did not meet any of the predefined objective criteria and approval by the 
DMID  MM will suffice for expansion of enrollment in the rest of the subjects in each cohort . If 
any of the halting rules  below  are met, further dosing  will be halted pending SMC review.  
At predefined time points  (Section  8.7), the SRC  will meet to review all safety data for the 
cohort in question to determine if the escalation -halting rules have been met.  In addition, the 
SDCC will provide study team with documentation of whe ther halting rules were/were not met 
after all the relevant safety data has been entered into the electronic data capture system  up to 
Day 14 for subjects in the cohort . If none of the rules has been met  through Day 14  into each 
cohort , the DMID MM will give approval for the next cohort to begin enrollment. If a 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   71 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 dose-escalation halting rule is met, the SMC will need to convene to recommend to DMID the 
next ste ps. 
Dose -escalation decisions will be documented by the DMID MM . This documentation will 
include whether halting criteria were met and, if applicable, any review and actions of the SMC.  
8.6.1 Sentinel Subject Halting Rules  
The site PI will review sentinel subject data from dosing thr ough Day 4 to confirm that sentinel 
subject(s) data have not m et predefined halting criteria and notify the DMID Medical Monitor 
prior to proceeding with dosing the remaining cohort . 
• Any SAE , regardless of the relationship to the study product  (with the exception of death 
or hospitalization that was th e result of trauma or accident).  
OR 
• A sentinel subject  within a cohort experience s a related  Grade 3 or higher AE (laboratory 
or systemic ) not resolved within 24 hours through Day 4.  Resolution is defined as down 
to Grade 1 or Baseline. Note: If the even t starts on Da y 4, the review period will be 
extended to Day 5  
If the predefined criteria for sentinel subject are met, the SMC will review the study data and 
provide guidance on how to proceed.  
8.6.2 Cohort Dose -Escalation Halting Rules  (Dosing through Day 14) 
• One subject has an SAE that is determined to be related  to the study product . 
OR 
• Two or more subjects in a cohort experience Grade 2 or higher  related  AE (laboratory or 
systemic ) that is coded in the same high level group term ( HLG T) per MedDRA  
classification.  
If the predefined criteria for dose escalation halting  are met, the SMC will review the study data 
and provide guidance on how to proceed . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   72 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 8.6.3 Study Halting Criteria  
• One subject has an SAE that is determined to be related  to study product . 
OR 
• Three or more subjects in the study (cumulative among all cohorts) experience a Grade 3 
related  AE (laboratory or systemic) that is coded in the same HLGT  per MedDRA 
classification . 
8.6.4 Infusion Halting Rules  
Infusion of the Investigational Product  will be halted if any of the following manifestations of 
anaphylaxis  develop and will not be restarted . Symptoms of anaphylaxis may begin in seconds or 
minutes  of infusion.  
• Skin or mucous membrane manifestations: hives, moderate or severe pruritus, or angioedema 
(usually of face, eyelids, or lips, tongue or uvula ). 
• Respiratory compromise: sensation of throat closure or choking, chest tightness, wheezing, 
stridor . 
• A decrease in systolic BP to < 90 mmHg or >  30% decrease from baseline in systolic or 
diastolic BP. 
• Tachycardia with an increase in resting heart rate to ≥  130 beats per minute (bpm); or 
development of a ventricular dysrhythmia; or bradycardia <  45 bpm (or <  40 bpm in subjects 
with a baseline of <  60 bpm) that is associated with complaints of dizziness, nausea, or 
feeling faint . 
• Syncope . 
• Slurred speech and/or confusion . 
• Any other condition that the site PI judges to unduly increase the risk to the subject . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   73 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Infusion related reactions  to monoclonal antibodies typically develop within 30 minutes to two 
hours after the initiation of drug infusion, although symptoms  may be delayed for up to 24 hours.  
The most common signs and symptoms of infusion reactions  are:  
• Fever and/or shaking chills  
• Flushing and/or itching  
• Alterations in heart rate and BP 
• Shortness of breath, chest discomfort  
• Nausea, vomiting, and/or diarrhea  
• Various types of skin rashes . 
In case of a suspected infusion -related reaction, the infusion can be stopped for up to 15 minutes 
and the subject observed to determine the severity of the reaction s. For grading of 
infusion -related reactions, refer to Appendix B  and NCI CTCAE, Version 5.0 – November  2017 ; 
see MOP for specific instructions regarding intervention. The decision to continue the infusion is 
based on the assessment by the investigator ; depending on the assessment of the subject, 
supportive care can be administered, and /or the infusion permanently stopped.  
The study  may also be suspended (subject enrollment and/or study interventions suspended) 
because of safety findings, such as an SAE or an overall pattern of symptomatic, clinical, or 
laboratory events that the DMID Medical Monitor or the SMC  consider associated wi th the study 
product. These may appear minor in terms of individual events, but might collectively represent 
potential concern for saf ety. 
The DMID Medical Monitor may stop enrollment and/or administration of study product if AEs 
that meet the halting crit eria are reported.  
 Safety Oversight ( SRC, SMC ) 
8.7.1 Data and Safety Monitoring Board  
Not applicable  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   74 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 8.7.2 Safety Review Committee  
The SRC will consist of a DMID Medical Monitor, Evotec medical officer, and the study/clinical 
site PIs. The SRC will review blinded comb ined safety data after each cohort .  
Safety data may include, but is not limited to, vital signs, safety laboratory assessments, AEs, 
physical exam findings , and any noted trends through Day 14 for current cohort. The site PI(s) 
review the data in real time and share findings with the DMID MM and Evotec medical officer . 
The PI will indicate whether any cohort dose escalation halting rules or study halting cri teria 
have been met and will provide a recommendation for dose escalation. Ad hoc SMC may be 
convened at recommendation of SRC in response to a safety issue.  
8.7.3 Safety Monitoring Committee  
A SMC will be utilized for this study and will be comprised of individ uals independent of the 
study, with relevant expertise, to advise DMID and the study investigators, will be established by 
DMID. SMC members will be separate and independent of study personnel participating in this 
study and should not have scientific, fin ancial, or other conflict s of interest related to the study. 
The SMC will consist of members with appropriate expertise to contribute to the interpretation of 
the data from this study. The SMC will operate under the rules of a DMID -approved charter. 
DMID o r the SMC chair may convene the SMC at specified times during the course of study as 
defined in the SMC Charter , or on an ad hoc basis according to protocol criteria , or if there are 
immediate concerns regarding observations during the course of the study.  The SMC for this 
study will review data at the following time points:  
• Organization meeting prior to the start of the study  
• Ad hoc review: In response to a safety issue such as a study -halting or 
dose-escalation -halting  rule being met.  
• Final Data Review: A n end of study summary of cumulative safety data will be provided 
for electronic review unless the SMC determines a data review teleconference is required.  
After each meeting the SMC will make written recommendations to DMID whether the study (or 
intervent ion for an individual or study cohort) should continue per protocol, proceed with 
caution, be further investigated, be modified and then proceed, or be terminated.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   75 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 HUMAN SUBJECTS PROTECTION  
 Institutional Review Board /Independent Ethics Committee  
This protocol, the ICF, and all relevant supporting information  must be submitted by each site PI 
to the IRB/IEC for approval. The protocol, ICF, and any advertisement used to recruit study 
subjects must be approved by the IRB/IEC. Approval by the IRB/IEC of the protocol and ICF 
must be obtained before the study may be initiated.  
The investigator is responsible for informing the IRB/IEC of any changes made to the protocol 
and to advise them, at least once a year, about the progress of the study. The  investigator is also 
responsible for notifying the IRB/IEC of any significant AEs that occur during the study.  
The site PI will obtain IRB approval for this protocol to be conducted at each clinical  site and 
send supporting documentation to the DMID befor e initiating recruitment of subjects  at the site . 
The investigator will submit applicable information to the IRB/IEC on which it relies for the 
review and will conduct the review in accordance with 45 CFR 46, ICH E6 GCP, and as 
applicable, 21 CFR 56 (IRBs)  and 21 CFR 50 (protection of human subjects), and other Federal, 
State, and Local Regulations. The IRB/IEC must be registered with OHRP as applicable to the 
research. DMID must receive the documentation that verifies IRB/IEC approval for this protocol, 
associated informed consent documents, and upon request , any recruitment material and 
handouts or surveys intended for the subjects, prior to the recruitm ent and enrollment of subjects.  
Any amendments to the protocol or consent materials will be approved by the IRB/IEC before 
they are implemented. IRB/IEC review and approval will occur at least annually throughout the 
enrollment and follow -up of subjects and may cease if annual review is no longer required by 
applicable regulations. The investigator will noti fy the IRB/IEC of deviations from the protocol 
and reportable SAEs, as applicable to the IRB/IEC policy.  
Each institution engaged in this research will hold a current FWA issued by the OHRP for 
federally  funded  research.  
A single IRB of record  will be acco untable for compliance with regulatory requirements for this 
multi -site study, at participating sites. A formal Reliance Agreement will be required between 
the single IRB and participating sites. The formal Reliance Agreement will set forth the specific 
responsibilities of the IRB and each participating site. Participating sit es will then rely on the 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   76 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 IRB of record to satisfy the regulatory requirements relevant to the IRB review. Participating 
sites will maintain essential required documentation of IRB reviews, approvals, and 
correspondence, and must provide copies of any agree ments and essential documentation to the 
DMID/SDCC or regulatory authorities upon request.  
 Informed Consent Process  
This study will be conducted in compliance with ICH E6 GCP: Consolidated Guidelines 
pertaining to informed consent. Subjects will give writt en consent to participate in the study at 
the first visit, before initiation of any study -related procedures, after having been informed about 
the nature and purpose of the study, participation and termination conditions, risks, and benefits. 
The subjects will be informed that participation is voluntary and that they are free to withdraw 
from the study for any reason at any time without penalty or loss of benefits to which the subject 
is otherwise entitled . The ICF must be signed and dated by the subject be fore study participation. 
A copy of the ICF must be provided to the subject . Signed consent forms must remain in the 
subject’s study file and be available for verification by the sponsor at any time.  
Informed consent is a process that is initiated prior to  an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. Before any study procedures 
are performed, informed consent will be obtained and documented. Subjects will receive a 
concise and focused prese ntation of key information about the clinical trial, verbally and with a 
written consent form. The explanation will be organized and presented in lay terminology and 
language that facilitates understanding why one might or might not want to participate.  
An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
risks and discomforts, any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.  
Subjects will also receive an explanation that the trial involves research and a detailed summary 
of the proposed study procedures and study interventions/products. This will include aspects  of 
the trial that are experimental, the probability for random assignment to treatment groups, any 
expected benefits, all possible risks (including a statement that the particular treatment or 
procedure may involve risks to the subject or to the embryo or  fetus, if the subject is or may 
become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in the trial, alternative procedures that may be available , and the important potential 
benefits and risks of these av ailable alternative procedures.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   77 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Subjects will be informed that records identifying the subject will be kept confidential, and, to 
the extent permitted by the applicable laws and/or regulations, will not be made publicly 
available and, if the results of the  trial are published, the subject’s identity will remain 
confidential. Subjects will be informed whether private information collected from this research 
and/or specimens will be used for additional research, even if identifiers are removed . 
Subjects will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their willingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical  treatments are 
available if injury occurs, and, if so, what they consist of, or where further information may be 
obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject 
for participating in the trial, as well as a ny anticipated prorated payments, if any, to the subject 
for participating in the trial. They will be informed of whom to contact (eg, the investigator) for 
answers to any questions relating to the research project.  
Illiterate Subjects  
If illiterate , subjects will be consented using  a short  form consent  that states the required 
elements of informed consent have been presented to the subject, with a witness present.  
 Consent for Future Use of Stored Specimens and Data  
No residual biological samples or data will be retained  for future use . 
 Exclusion of Women, Minorities, and Children (Special Populations)  
Women who are pregnant and/or nursing and children will be excluded from this study as the 
risks of the study product  during pregnancy  and nursing  and in children have not been evaluated.  
 Subject Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and 
the sponsors and th eir agents. This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other information generated during participation in the 
study. No information concerning the study or the data generated from the study wil l be released 
to any unauthorized third party without prior written approval of the DMID and the subject. 
Subject confidentiality will be maintained when study results are published or discussed in 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   78 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 conferences. The study monitor or other authorized represe ntatives of the sponsor or 
governmental regulatory agencies may inspect all documents and records required to be 
maintained by the investigator, including but not limited to, medical records (office, clinic, or 
hospital) and pharmacy records for the subjec ts in this study. The clinical study site will permit 
access to such records.  
All records will be kept locked , and all computer entry and networking programs will be carried 
out with coded numbers only and with password -protected systems.  All nonclinical s pecimens, 
evaluation forms, reports, and other records that leave the site will be identified only by a coded 
number.  
 Certificate of Confidentiality  
To protect privacy, we have received a C ertificate of Confidentiality. With this Certificate, the 
researchers cannot be forced to release information that may identify the research subject, even 
by a court subpoena, in any Federal, State, or Local civil, criminal, administrative, legislative, or 
other proceedings. The researc hers will use the Certificate to resist any demands for information 
that would identify the subject, except as explained below.  
The Certificate cannot be used to resist a demand for information from personnel of the United 
States Government that is used fo r auditing or evaluation of federally  funded projects, like this 
study, or for information that must be released in order to meet the requirements of the FDA.  
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
informat ion about themselves or their involvement in this research. If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the 
Certificate  to withhold that information.  
The Certificate of Confidentiality  does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that mus t be legally reported including  child and elder abuse, sexual 
abuse, or wanting  to harm themselves or others.  
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or for the pu rposes of other research that is in compliance with applicable Federal 
regulations governing the protection of human subjects in research.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   79 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subjects for the research tests, proce dures, and study product while taking part 
in this trial. Procedures and treatment for clinical care may be billed to the subject, subject’s 
insurance, or third party. Subjects may be compensated for their participation in this trial. 
Compensation will be in accordance with the IRB’s policies and procedures and subject to IRB 
approval.  
If it is determined by the site PI that an injury occurred to a subject as a direct result of the tests 
or treatments that are done for this trial, referrals to appropriate h ealth care facilities will be 
provided to the subject. Study personnel will try to reduce, control, and treat any complications 
from this trial. Immediate medical treatment may be provided by the participating site. No 
financial compensation will be provid ed to the subject by the NIAID, NIH  for any injury 
suffered due to participation in this trial.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   80 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 STATISTICAL CONSIDERATIONS  
 Study Hypotheses  
There are no formal hypotheses being tested in this Phase 1 study . The objectives of this study 
are to evaluate the safety , PK, and immunogenicity  profiles of single ascending doses of IV 
SAR440894  in healthy adults . 
 Sample Size Considerations  
No formal sample -size calculations based on testing a statistical hypothesis were performed. This 
study plans to randomize 40 subjects. The number of subjects was selected to allow sufficient 
evaluation of safety, and PK of the various single dose regimens  to be administered in this study 
and is consistent with standards of practice for Phase 1 studies.  
 Treatment Assignment Procedures  
10.3.1  Randomization Procedures  
This is a Phase 1 , randomized,  double -blinded, placebo -controlled , multi -site study  that will 
rando mize subjects within 5 cohorts to either SAR440894  or placebo  in an overall 3:1 ratio  
(Table  3-1). For each cohort, the first  2 sentinel subjects will be randomized in a 1:1 ratio to 
SAR440894  and pl acebo to ensure that 1 of the first 2 subjects receives IV infusion of 
SAR440894 and the other IV placebo. The remaining 6  subjects in each cohort will be 
randomized in a 5:1 ratio to SAR440894  and placebo  after confirmation that sentinel subject 
halting rules have not been met . If replacements are needed, each replacement subject will 
receive the same treatment as the originally randomized subject . 
Randomized treatment assignments will be generated by a statistician at Emmes , the SDCC for 
this study. Subjects will be registered using a web -based application dev eloped by Emmes.  
After informed consent has been obtained and study eligibility has been established, subjects will 
be admitted to the clinical site  within approximately 24 hours before the first dose of study 
product  is administered.  Randomization will oc cur following admi ssion  to the unit and 
confirmation of eligibility . 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   81 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Per ICH guideline E6: GCP, Screening records will be kept at the participating site to document 
the reason  why an individual was screened  but failed trial entry criteria. The reasons why 
individuals failed Screening will be recorded in the SDCC Advantage eClinical® (electronic data 
capture system).  
Enrollment of subjects will be done online using the registration module  of Advantage 
eClinical®. The randomization code will be prepared by st atisticians at the SDCC and included in 
the registration module  for this trial. Advantage eClinical® will assign each subject to a treatment 
arm after the demographic and eligibility data have been entered into the system. A designated 
individual at the pa rticipating site will be provided with a code list, which will be kept in a 
secure place , for emergency unblinding purposes.  
Instructions for use of the registration module  are included in the Advantage eClinical® User’s 
Guide.  Manual back -up procedures and instructions are provided for use in the event that a 
participating site temporarily loses access to the Internet or the online enrollment system is 
unavailable.  
10.3.2  Masking Procedures  
All study personnel, including the s ponsor, site investigators,  study  personnel involved in study 
conduct, and subjects will remain blinded to study product  assignment until the study is 
completed and the database is locked , with the exception of the SDCC  and p harmac ist to prepare 
drug and monitor drug accountability during the study , and cases in which unblinding is required 
due to a safety issue. To maintain study blinding, study product  preparation will be performed by 
an unblinded site pharmacist  (or qualified unblinded personnel not involved wi th study 
procedures or evaluations , at the study site). If unblinding is necessary  to maintain subject safety , 
an unblinded statistician may be engaged to confirm if any of the impacted subjects were 
administered SAR440894 . 
Instructions for study product  preparation and dosing are outlined in the MOP , provided  
separately to the site. If the dose level is determined to have safety  concerns, the study product  
assignment for the subjects with the safety issue may be unblinded . The sponsor may also 
independentl y decide to unblind the entire cohort or terminate enrollment. In the case of a 
medical emergency requiring the site PI to know the identity of the study product , the site PI will 
follow the procedures outlined in Section  10.3.3 . 
The SMC may receive data in aggregate and presented by cohort. The SMC will review grouped 
(by treatment)  and unblinded data in closed session only.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   82 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Blinding  of bioanalytical staff will be achieved through use of the SDCC GlobalTrace electronic 
specimen tracking system in combination with unique sample barcodes. The system provides all 
trial specimens with a masked label (barcode) in order to blind both the DM ID CAR and the 
laboratories that receive trial specimens. This masked label ensures the integrity of the data. 
Custom specimen labels that eliminate this safeguard (eg, labels that include the subject ID 
and/or time point) will not be used. Further details  will be described in the MOP.  
10.3.3  Breaking the Blind  
This study is a double -blind design. The site PI, study personnel, and subjects will not make any 
effort to determine which study product  is being received. Unblinded pharmacy personnel or 
unblinded study p ersonnel (ie, PK analyst and statistician) may be utilized in this study.  
Only in the case of an emergency, when knowledge of the study product  is essential for the 
clinical management or welfare of a specific subject, may the PI unblind a subject’s treatm ent 
assignment.  
Before any unblinding, the site PI is strongly advised to discuss options with the DMID Medical 
Monitor or appropriate sponsor study personnel. As soon as possible and without revealing the 
subject’s study product  assignment (unless importa nt to the safety of subjects remaining in the 
study), the PI mu st notify the sponsor within 24  hours if the blind is broken for any reason and 
the PI was unable to contact the sponsor before unblinding. The site will record unblinding as a 
protocol deviation  and document the date and reason for revealing the blinded treatment 
assignment for that subject.  
 Planned Interim Analyses  
10.4.1  Interim Safety Review  
Safety reviews will occur by the SRC and SMC as outlined in Section  8.7. Halting rules are 
outlined in Section  8.6. Safety will be evaluated by presenting summaries of AEs, clinical 
laboratory evaluations (hematology evaluation, chemistry and coagulation  panel, and urinalysis ), 
vital signs, and ECGs. Safety variables will be tabu lated by cohort  and presented for all subjects 
in the safety population.  
 Final Analysis Plan  
The ICH/ FDA Guidance Document E9 (Statistical Principles for Clinical Trials) will be followed 
for all statistical content. For categorical data, summaries of frequencies and percentages will be 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   83 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 presented. Summaries for continuous data may include minimum, median,  mean, SD, and 
maximum. All data will be summarized separately by dose group  and study product . Listings of 
individual subject data will also be produced.  Detailed summaries of the PK , immunogenicity  
and other analyses will be prospectively described in a statistical analysis plan (SAP)  prepared 
by the SDCC statistician before unblinding of subjects . All final analyses will be performed by 
the SDCC statisti cian after the data are locked.  Unless specified otherwise in the SAP, missing 
data will not be impute d. 
All subjects receiving placebo will be combined across cohorts into a sin gle placebo group for 
analysis.  Missing data for outcome measures will not be imputed.  
10.5.1  Safety Analysis Plan  
Safety will be evaluated by presenting summaries of AEs, clinical labora tory evaluations 
(hematology evaluation, coagulation, chemistry panel, and urinalysis ), vital signs , physical exam, 
and ECGs . Safety variables will be tabulated by dose group and presented for all subjects in the 
safety population.  The safety population will include a ll subjects who receive any study product  
and will be grouped by treatment received . 
10.5.1.1  Adverse and Serious Adverse Events  
Adverse events will be coded using MedDRA  Version 2 5.1 or higher . The incidence of TEAEs 
will be pr esented by system organ class , high-level group term, and  preferred term according to 
MedDRA, by relationship to the study product , by severity, and by whether or not they resulted 
in alteration of administration of or discontinuation of study product . In addition, the incidence 
of serious TEAEs and TEAEs leading to discontinuation of study product  will be presented by 
system organ cl ass, high -level group term, preferred term , and relationship to study product . 
10.5.1.2  Clinical Safety Labs, Vital Signs,  and Electro cardiograms  
Descriptive statistics for clinical laboratory test results, vital signs, and ECG intervals, including 
changes from baseline, will be presented by time point and dose group. Baseline is defined as the 
measurement closest to, but before, the adm inistration of study product . If triplicate 
measurements were performed at the same visit, then baseline is the mean  value of the 
measurements for the visit closest to, but before, administration of study product . Similarly, for 
analyses of change from bas eline, mean  values will be used in the case of replicate 
measurements at a single visit post  baseline. Laboratory results and vital signs  obtained after 
start of dosing  will be graded according to criteria  Appendix C  and Appendix D  for subjects who  
screened and enrolled prior to Protocol Version 11 .0 and NCI CTCAE, Version 5.0 – 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   84 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 November  2017 for subjects who screen and enroll with Protocol Version 11.0  and summarized. 
Summaries of vital signs and ECG assessments will be analyzed at Screening and post dose 
using descriptive statistics . 
10.5.2  Pharmacokinet ic Analysis Plan  
Details of the PK analysis plan will be included in the SAP. Blood samples from all s ubjects who 
received a complete dose of SAR440894 (the PK population) will be analyzed for the 
concentration of SAR440894  by a validated enzyme -linked immunosorbent  assay  methodology . 
Plasma  concentration -time curves will be constructed for each subject and each dose group . An 
optional review of SAR440894 time -concentration trends may be performed following each 
cohort.  For each plasma  profile, PK parameters  including, but not limited to, half -life, C max, 
minimum observed plasma concentration ( Cmin), time of the maximum observed plasma 
concentration ( Tmax), AUC, clearance, and volume of distribution  will be estimated by 
noncompartmental  analysis methods using Version  8.0 or higher of Phoenix WinNonlin®. 
10.5.3  Immunogenicity Analysis Plan  
A positive result will be defined as a positive Screening assay followed by a positive 
confirmatory assay and a negative result will be defined as a negative Screening assay or a 
positive Screening assay followed by a negative confirmatory assay. By dose group and post -
dose time point, ADA results will b e summarized as negative, treatment -induced ADA (negative 
result at baseline and positive result post -dose), treatment -boosted ADA (positive both at both 
baseline and post -dose, with a 4 -fold or 9 -fold increase to titer as defined in the SAP ), or 
pre-exist ing ADA (ADA present both at baseline and post -dose, but not treatment -boosted) . 
Incidence of ADA (defined as either treatment -induced or treatment -boosted ADA at any time 
point) will be summarized by dose group. ADA titers may be determined in the case of  positive 
ADA results. If determined, summary statistics ADA titers  and possibly fold change from 
baseline in titer  will be summarized by dose group and time point. If five or more subjects have 
positive ADA  results , the effect of ADA on the clearance of SAR440894  may be explored.  
Additionally, the proportion of subjects with a positive Screening assay result will be 
summarized by dose group and time point.  ADA results may be analyzed between dosing 
cohorts.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   85 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUME NTS  
Each participating site will maintain appropriate medical and research records in compliance 
with ICH E6, Secti on 4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects. Each site will permit authorized repr esentatives of the DMID, its 
designees, and appropriate regulatory agencies to examine (and when required by applicable law, 
to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of 
the study safety and progress. T hese representatives will be permitted access to all source data  
and source documents , which include, but are not limited to, hospital records, clinical and office 
charts, laboratory notes, memoranda, subjects’ memory aid or evaluation checklists, pharmacy  
dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, and subject files and records kep t at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   86 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, the site  is responsible for 
conducting routine quality assurance and quality control activities to internally monitor study 
progress and protocol compliance. The site PI will provide direct access to all study -related 
source data/data collection forms, and reports for  the purpose of monitoring and auditing by the 
sponsor, and inspection by loc al and regulatory authorities. The site PI will ensure all study 
personnel are appropriately trained and applicable documentations are maintained on site.  
The SDCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site (s) for clarification and resolution.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   87 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 DATA HANDLING AND RECORD KEEPING  
Each participating site will maintain appropriate medical and research records for this clinical 
trial, in compliance with ICH E6  GCP Section 4.9 and regulatory and institutional requirements 
for the protection of confidentialit y of subjects. The site will permit the study monitor or other 
authorized representat ives of DMID as well as  governmental  regulatory agencies , such as the 
FDA,  to examine (and when required by applicable law, to copy) clinical trial records for the 
purpose s of quality assurance reviews, audits, monitoring and evaluation of the study safety and 
progress. These representatives will be permitted access to all source data, which include, but are 
not limited to, hospital records, clinical and office charts, labo ratory notes, memoranda, 
evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or m agnetic media, x -rays, and subject files , and records kept 
at the pharmacy, at the laboratories and medico -technical departments involved in this clinical 
trial. Source data are all information, original records of clinical findings, observations, or other  
activities in a clinical trial necessary for the reconstruction and evaluation of the clinical trial. 
Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records 
from the subject’s primary care provider is not requir ed. 
Training sessions, regular monitoring of investigators by sponsor -designated personnel, 
instruction manuals, data verification, crosschecking, and data audits will be performed to ensure 
quality of all study data. Investigator meetings will be performe d to prepare investigators and 
other study personnel for appropriate collection of study data.  
 Data Management Responsibilities  
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of 
the data reported. All sourc e documents should be completed in a neat, legible manner to ensure 
accurate interpretation of data. Black  or blue permanent  ink is required to ensure clarity of 
reproduced copies. When making changes or corrections, cross out the original entry with a 
single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   88 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 Electro nic CRF (eCRF)  
Copies of the electronic CRF (eCRF) will be provided for use as source data collection forms 
and maintained for recording data for each subject enrolled in the study. Data reported in the 
eCRF derived from source data collection forms should  be consistent or the discrepancies should 
be explained.  
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site PI. During the study, the site PI must maintain complete and 
accurate documentation for the study.  
The SDCC  for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
 Data Capture Methods  
Clinical data (including, but not limited to, AE/SAEs, concomitant medicati ons, medical history, 
physical exam findings , and clinical laboratory values), immunogenicity  data, and PK data will 
be entered into a 21 CFR 11 -compliant Internet Data Entry System provided by the SDCC. The 
data system includes password protection and int ernal quality checks, such as automatic range 
checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be 
entered directly from the data collection forms or original source completed by the study 
personnel.  
The eCRF will be supplied the SDCC  for the recording of all information and study data as 
specified by this protocol. All eCRFs must be completed by trained study personnel. The 
investigator is responsible for ensuring that the eCRF data are entered and completed i n a timely 
manner.  
 Types of Data  
Data for this study  will include clinical, safety, immunogenicity, and PK measures.  
 Study Records Retention  
Study records and reports including, but not limited to, eCRFs, source documents, ICFs, 
laboratory test results, and medication inventory records, s hall be retained for at least 6  years 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   89 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 after the study i s completed, but no less than 2  years after a marketing application is approved for 
the drug; or, if an application is not  approved for the drug, until 2  years after shipment and 
delivery of the drug for investigational use is discontinued and the FDA has been so notified. 
The site must contact DMID for authorization before destroying any study records.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   90 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 CLINICAL MONITORING  
Site monitoring is conducted to ensur e that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is 
conducted in accordance with the protocol, protocol -specific MOP , and applicable sponsor 
SOPs . DMID, the sponsoring agency, or its designee will conduct site -monitoring visits as 
detailed in the clinical monitoring plan.  
Site visits (in-person or remote, as appropri ate) will be made at intervals defined by the clinical 
monitoring plan and may be made more f requently as directed by DMID. Monitoring visits will 
include, but are not limited to, review of regulatory files, accountability records, eCRFs, ICFs , 
medical and  laboratory reports, and protocol and GCP compliance. Site monitors will have 
access to each participating site, study personnel, and all study documentation  according to the 
DMID -approved site monitoring plan. Study monitors will meet with the site PIs to discuss any 
problems and actions to be taken, and will document site visit findings and discussions.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   91 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 PUBLICATION POLICY  
Following completion of the study, the lead PI is expected to publish the results of this research 
in a scientific journal. All investigators funded by the NIH must submit or have submitted for 
them to the National Library of Medicine’s PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/ ) 
an electronic version of their final, peer -reviewed manuscripts upon acceptance for publication, 
to be made publ icly available no later than 12  months after the official date of publication. The 
NIH Public Access Policy ensur es the public has access to the published results of NIH -funded 
research. It requires investigators to submit final peer -reviewed journal manuscripts that arise 
from NIH funds to the digital archive PubMed Central upon acceptance for publication. Further, 
the policy stipulates that these papers must be accessible to the public on PubMed Central no 
later than 12  months after publication.  
Refer to:  
NIH Public Access Policy, http://publicaccess.nih.gov/  NIH Office of Extramural Research 
Grants and Funding, http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by the NIH must be registered on 
Clini calTrials.gov, no later than 21  days after the enrollment of the first subject. R esults of all 
clinical trials supported by the NIH, generally, need to be submitted no later th an 12  months 
following the primary completion date.  
As part of the result posting, a copy of this protocol (and its amendments) , and a copy of the 
Statistical An alysis Plan will be posted on ClincialTrials.gov. For this trial the responsible party 
is DMID/NIAID/NIH, which will register the trial and post results.  
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   92 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 LITERATURE REFERENCES  
1.  Chikungunya. https://www.who.int/news -room/fact -sheets/detail/chikungunya. Accessed 
July 3, 2019.  
2.  Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman -Thio E. Monoclonal 
antibody -induced cytokine -release syndrome. Expert Rev Clin Immunol . 2009 ;5(5):499 -521. 
doi:10.1586/eci.09.31  
3.  Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of 
monoclonal antibodies. Nat Rev Drug Discov . 2010;9(4):325 -338. doi:10.1038/nrd3003  
4.  National Cancer Institute Common Term inology Criteria for Adverse Events (NCI CTCAE);  
Version 5.0, 27 November 2017.  
 
DMID Protocol 18 -0006 Version 11.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   93 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 APPENDICES  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
 
 
DMID/NIAID/NIH   94 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 SCHEDULE OF EVENTS  
Study Visit  Screening1 Admit 
to Unit  Confinement and 
Infusion  Discharge 
from Unit  Follow -Up Visits  Final 
Visit  Early  
Term  Unscheduled 
Visit  
Study Day  
±Window  -45 to -2 -1 1 2 3 4 7 
±1 14 
±2 28 
±4 56 
±4 84 
±7 112 
±7 150 
±7 NA  
Obtain informed 
consent  X               
Record 
demographics  X               
Review inclusion/ 
exclusion criteria  X X              
Review medical 
history  X X X12            X 
Review 
concomitant 
medications2 X X X12 X X X X X X X X X X X X 
Review 
contraception/  
menses  X X X   X X X X X X X X X  
Height/weight /BMI  X X16              
Perform complete 
physical 
exam ination3 X X    X       X X  
Perform 
symptom -directed   X12,13 X13 X13  X X X X X X   X 
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
 
 
DMID/NIAID/NIH   95 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Study Visit  Screening1 Admit 
to Unit  Confinement and 
Infusion  Discharge 
from Unit  Follow -Up Visits  Final 
Visit  Early  
Term  Unscheduled 
Visit  
Study Day  
±Window  -45 to -2 -1 1 2 3 4 7 
±1 14 
±2 28 
±4 56 
±4 84 
±7 112 
±7 150 
±7 NA  
physical 
exam ination  
Obtain vital signs4 X X X12,14 X4 X4 X X X X X X X X X X 
Obtain Screening 
labs5 X               
Obtain clinical 
safety labs6  X  X X X X X X X X X X X  
Renal injury 
biomarker  
(serum cystatin -C)  X  X X X X X X X X X X X  
Serum β -hCG7 X X              
Urine pregnancy 
test         X  X  X X  
Urine dipstick8 X X  X X X X X X X X X X X  
Urine toxicology  X X              
Breathalyzer  X X              
Immunogenicity 
(ADA )   X12       X  X X X  
Hypersensitivity 
panel    X12,15           X15  
12-lead ECG9 X  X   X       X X  
Viral serology10 X               
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
 
 
DMID/NIAID/NIH   96 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Study Visit  Screening1 Admit 
to Unit  Confinement and 
Infusion  Discharge 
from Unit  Follow -Up Visits  Final 
Visit  Early  
Term  Unscheduled 
Visit  
Study Day  
±Window  -45 to -2 -1 1 2 3 4 7 
±1 14 
±2 28 
±4 56 
±4 84 
±7 112 
±7 150 
±7 NA  
Obtain PK 
samples11   X X X X X X X X X X X X  
Randomization   X              
Study product  
administration    X             
Counsel on the 
avoidance of 
pregnancy  and 
prohibited 
medications/ 
substances  X     X X X X X X X  X  
Counsel on 
avoidance of 
vaccines       X X X X X      
AE review    X X X X X X X X X X X X  
SAE review    X X X X X X X X X X X X  
1. Screening will be completed within 45 days prior to administration of study product  and may require more than one visit.  
2. Concomitant medications including all of the following: prescription drugs, over -the–counter drugs, herbs, vitamins, nutritional supplements, illicit and recreational substance 
use, vaccines,  birth control information.  
3. Complete physical examination  includes general appearance, head, ears, eyes, nose, throat, dentition, thyroid, chest (heart, lungs), abdomen, skin, neurological, ex tremities, 
back, neck, musculoskeletal, lymph nodes.  
4. Vital signs include supine diastolic and systolic BP, heart rate, respiratory rate and oral temperature . Vital signs will be collected in singlicate unless part of AE/SAE 
assessment. If AE/SAE involving BP or heart rate  occurs, vital signs will be collected in triplicate  from the same arm at least 5 minutes apart.  At Screening and o n Days -1, 
2, 3, and all Follow up visits, measure vital signs prior to blood collection.  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
 
 
DMID/NIAID/NIH   97 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 5. Screening laboratory tests are outlined in Table  7-1 and Section  6.2. 
6. Clinical safety lab oratory  tests are outlined in  Table  7-1, Section 6.3, and Section 6.4. 
7. A serum  pregnancy test will be obtained for all women of reproductive capacity at Screening and within approximately 24 hours before study product administration. Results 
must be confirmed as negative before study product infusion begins. An FSH level will be checked in female participants reporting postmenopausal status.  
8. A urine dipsti ck will be done to evaluate for presence of protein, glucose , or blood in urine. If dipstick is abnormal, a complete urinalysis with microscop y will be performed.   
9. A 12 -lead ECG will be done during Screening  (triplicate ), within 60 -minutes prior to dosing (triplicate),  at the end of the infusion of the study product +15 min utes (triplicate , 
±5 minutes ), and prior to discharge  (triplicate ). Continuous remote telemetry monitoring will be conducted from 30 minutes prior to study product administration to 
approximately 4 hours post dose.  
10. Viral serology includes CHIKV  antibody , HIV antibody , HB  surface antigen  and antibody to HCV.  
11. Plasma PK samples will be taken at the following times  with an acceptable window of  60-minutes prior to dosing; ±10 minutes in the first 8 hours after dosing ; and 
±30 minutes between 9 and 72  hours : within 5 minutes of  the completion of the infusion, and at: 1, 4, 8 , 12, 24, 48, and 72 hours  relative to the end of the infusion  time, and 
on Day 7 ±1, Day 14  ±2, Day 28  ±4, Day 56 ±4, Day 84  ±7, Day 112  ±7, Day 150 ±7, and ET (if needed) . PK samples at Follow -up visits will be collected during the 
designated Follow -up window.  
12. Occurs prior to dosing  on Day 1 and is considered to be the baseline sample . 
13. A symptom -directed physical exam will be performed prior to infusion  and after (as needed ) to assess potential/active AEs  and signs and symptoms of infusion reactions .  
14. Vital signs will be checked  within a 60 -minute period prior to dosing and every 1 5 minutes  (±5 minutes)  during the infusion. After the infusion, vital signs  will be taken at the  
following time points: 1, 2, 4, and 6  hours  with an acceptable window of ±5 minutes for each time point.  
15. Draw 1 2 mL prior to dosing. If a subject develops anaphylaxis or anaphylac toid reaction, three  additional 1 2 mL sample s will be collected: during onset, 2 or more hours after 
onset, and after resolution of symptoms.  
16. Measure only weight on Day  -1. Day -1 weight will be used for dose calculations.  
 
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   98 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 TOXICITY TABLE  
Clinical Adverse Events  
CARDIOVASCULAR 
TOXICITY  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Arrhythmia1 N/A Asymptomatic; transient 
signs; no medical 
intervention required  Recurrent/persistent; 
symptomatic medical 
intervention required  
Hemorrhage, Blood Loss  Estimated blood loss 
≤ 100 mL  Estimated blood loss 
> 100 mL, no 
transfusion required  Transfusion required  
QTc (Fridericia’s correction)2 Females:  
QTc interval 
> 470-479 msec  QTc interval 480 to 499 
msec OR Increase in 
interval 30 -50 msec 
above baseline  QTc interval ≥ 500 msec 
OR Increase in interval 
> 50 msec above 
baseline  
Males:  
Asymptomatic, QTc 
interval > 450-479 msec  
RESPIRATORY 
TOXICITY  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Cough  Transient; no treatment  Persistent cough  Interferes with daily 
activities  
Bronchospasm, Acute  Transient; no treatment; 
71% - 80% FEV1 of 
predicted peak flow  Requires medical 
intervention; normalizes 
with bronchodilator; 
FEV1 60% - 70% (of 
predicted peak flow)  No normalization with 
bronchodilator; FEV1 
< 60% of predicted peak 
flow 
Dyspnea  Does n ot interfere with 
usual and social 
activities  Interferes with usual and 
social activities; no 
treatment  Prevents daily and usual 
social activity OR 
requires treatment  
 
 
1 Sinus arrhythmia is a normal variant and will not be considered an adverse event.  
2 Inclusion dependent upon protocol requirements.  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   99 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 GASTROINTESTINAL 
TOXICITY  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Nausea  No interference with 
activity  Some interference with 
activity  Prevents daily activities  
Vomiting  No interference with 
activity OR 1 - 2 
episodes/24 hours  Some interference with 
activity OR >  2 
episodes/24 hours  Prevents daily activity 
OR requires IV 
hydration OR requires 
medical intervention  
Diarrhea  2 - 3 loose or watery 
stools or 
< 400 gm/24  hours  4 - 5 loose or watery 
stools or 400 – 
800 gm/24 hours  6 or more loose or 
watery stools or 
> 800 gm/24 hours OR 
requires IV hydration 
OR requ ires medical 
intervention  
LOCAL  REACTIONS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Pain Does not interfere with 
activity  Repeated use of non -
narcotic pain reliever for 
more than 24 hours or 
interferes with activity  Any use of narcotic pain 
reliever or prevents 
daily activity  
Tenderness  Discomfort only to 
touch  Discomfort with 
movement  Significant discomfort at 
rest 
Erythema or Redness 
(measure local reaction at the 
greatest single diameter)  25 - 50 mm  51 - 100 mm > 100 mm 
Induration or Swelling  25 - 50 mm and does not 
interfere with activity  51 - 100 mm or 
interferes with activity  > 100 m m or prevents 
daily activity  
SYSTEMIC REACTIONS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Allergic Reaction  Pruritus without rash  Localized urticaria OR 
requires oral therapy  Generalized urticaria; 
angioedema OR 
anaphylaxis OR requires 
epinephrine  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   100 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Infusion Related Reaction  
(Cytokine Release Syndrome)  Mild transient reaction, 
and Infusion interruption 
(ie, antibody infusion) 
not indicated  Infusion interruption 
indicated  but responds 
promptly to 
symptomatic treatment 
(eg, antihistamines, 
NSAIDS); prophylactic 
medication indicated for 
< 24 hours Prolonged severe signs 
and symptoms or 
Recurren ce of symptoms 
following initial 
improvement; 
hospitalization indicated 
for clinical sequelae  
Headache  No interference with 
activity  Repeated use of non -
narcotic pain reliever 
> 24 hours OR some 
interference with 
activity  Significant; any use of 
narcotic  pain reliever 
OR prevents daily 
activity OR requires 
triptans  
Fatigue  No interference with 
activity  Some interference with 
activity  Significant; prevents 
daily activity  
Myalgia  No interference with 
activity  Some interference with 
activity  Significant; prevents 
daily activity  
All Other Conditions  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Illness or Clinical Adverse 
Event (as defined according to 
applicable regulations)  No interference with 
activity  Some interference with 
activity not requiring 
medical intervention  Prevents daily activity 
and requires medical 
intervention  
Note: This toxicity table is to be used for subjects who screened and enrolled prior to Protocol Version 11.0. Subjects who 
screen and enroll with Protoc ol Version 11.0, toxicity will be assessed with the  NCI CTCAE, Version 5.0 – November  2017.  
 
  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   101 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 LABORATORY AND VITAL SIGNS ELIGIBILITY 
RANGES AND TOXICITY RANGES  
For use by Duke Clinical Laboratory  
 Reference 
Range a LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
Blood, Serum, or Plasma Chemistries d 
Sodium (m mol/L) 
135 – 145 LO < LLN - 132 131 - 130 < 130 
HI > ULN - 148 149 - 150 > 150 
Potassium (m mol/L) 
3.5 - 5.0 LO < LLN - 3.1 < 3.1 - 3.0 < 3.0 
HI > ULN - 5.2 5.3 - 5.4 > 5.4 
Bicarbonate/CO2 (mmol/L)  
21 – 30 LO 20 - 17 16 - 12 < 12 
HI 31 - 35 36 - 40 > 40 
Glucose (mg/dL)  
70 - 99 e LO 69 - 65 64 - 55 < 55 
HI > ULN - 120 121 - 130 > 130 
70 – 140 f HI 141 - 159 160 - 200 > 200 
Blood Urea Nitrogen (mg/dL)  
7 – 20 HI 21 - 26 27 - 31 > 31 
Creatinine (mg/dL)  Female:   0.4 – 
1.0 HI > ULN - 1.7 1.8 - 2.0 > 2.0 
Male:  0.6 – 1.3 
eGFR (mL/min/1.73 m2) 
by Modification of Diet in 
Renal Disease (MDRD) 
equation  ≥ 60 
mL/min/1.73 
m2 LO 59 - 45 44 - 30 < 30 
Calcium (mg/dL)  
8.7 - 10.2 LO < LLN - 8.0 7.9 - 7.5 < 7.5 
HI > ULN - 11.0 11.1 - 11.5 > 11.5 
Albumin (g/dL)  3.5 - 4.8 LO 3.4 - 2.8 2.7 - 2.5 < 2.5 
Total Protein (g/dL)  6.2 – 8.1 LO < LLN - 5.5 5.4 - 5.0 < 5.0 
Alkaline Phosphatase (U/L)  24 – 110 N 111 - 240 241 - 360 > 360 
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   102 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  Reference 
Range a LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
AST (U/L) 15 – 41 HI 42 - 105 106 - 175 > 175 
ALT (U/L) Female: 14 -54 HI 55 – 105 106 – 175 >175  
Male: 17 -63 HI 64 - 105 106 - 175 > 175 
 
Bilirubin, Serum Total 
(mg/dL)  0.4 – 1.5 HI 1.6 - 2.0 2.1 - 2.5 > 2.5 
Hematology d 
Hemoglobin (g/dL) 
     Females  12.0 – 15.5 LO 11.9 - 11.0 10.9 - 9.5 < 9.5 
     Males  13.7 – 17.3 LO 13.6 - 12.0 11.9 - 10.0 < 10.0 
WBC (109/L) 
3.2 – 9.8 LO 3.19 - 2.50 2.49 - 1.50 < 1.50 
HI 9.90 – 14.99  15.00 - 20.00  > 20.00  
Lymphocytes (109/L) 0.6 – 4.2 LO 0.59 – 0.50 0.49 - 0.40 < 0.40 
Neutrophils (109/L) 2.0 – 8.6 LO 1.99 - 1.50 1.49 - 1.00 < 1.00 
Eosinophils (109)/L 0.00-0.70 HI 0.71 - 0.75 0.76 - 1.50 > 1.50 
Platelets (109/L) 150 – 450 LO 149 - 120 119 - 100 < 100 
Coagulation  
Prothrombin Time (seconds)  9.5 – 13.1 HI > ULN - 14.4 14.5 - 15.7 > 15.7 
Prothrombin INR  0.9 – 1.1 HI 1.2-1.4 1.5-2.0 >2.0 
Partial Thromboplastin Time 
(seconds)  26.8 – 37.1 HI > ULN - 42.1 42.2 - 50.0 > 50.0 
Urine  
Protein  Negative  HI 1+ 2+ > 2+ 
Glucose  Negative  HI 1+ 2+ > 2+ 
Bilirubin  Negative  HI 1+ 2+ > 2+ 
Nitrite  Negative  HI Positive  N/A N/A 
Blood (microscopic) —red 
blood cells per high power 
field (rbc/hpf)  0 – 3 HI 4 - 10 11 - 50 > 50 and/or 
gross blood  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   103 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  Reference 
Range a LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
WBC (microscopic) —white 
blood cells per high power 
field (wbc/hpf)  0 – 5 HI 6 - 10 11 - 50 > 50 and/or 
gross blood  
Urobilinogen (mg/dL)  0.2 – 1.0 HI > ULN – 1.5 1.6 – 2.0 > 2.0  
Vital Signs  
Fever (°C) g  HI 38.0 - 38.4 38.5 - 38.9 > 38.9 
Fever (°F) g  HI 100.4 - 101.1  101.2 - 102.0  > 102.0  
Tachycardia —beats per 
minute   
HI 101 - 115 116 - 130 > 130 or 
ventricular 
dysrhythmias  
Bradycardia —beats per minute  
     Baseline ≥ 60   LO 54 - 50 49 - 45 < 45 
     Baseline < 60  LO 50 - 45 44 - 40 < 40 
Hypertension (systolic) —mm 
Hg h  HI 141 - 150 151 - 160 > 160 
Hypertension (diastolic) —
mm Hg h  HI 91 - 95 96 - 100 > 100 
Hypotension (systolic) —mm 
Hg h  LO 89 - 85 84 - 80 < 80 
Tachypnea - breaths per 
minute   HI 23 - 25 26 - 30 > 30 
Note: This table is to be used for subjects who screened and enrolled prior to Protocol Version 11.0. Subjects who screen and 
enroll with Protocol Version 11.0, toxicity will be assessed with the  NCI CTCAE, Version 5.0 – November  2017 . 
a Reference range of  Duke Clinical  laboratory.  
b High, Low, Not Graded.  
c If initial bound of Grade 1 has gap from reference range, calculations based on New England Journal of Medicine  reference 
ranges.  
d Depending upon the lab used, references ranges and grading may be split out by sex and/or age.  
e Fasting  > 8hours 
f Non-fasting ; includes subjects fasting ≥ 2 h ours and < 8 hours .  
g Oral temperature. A protocol should select either °C or °F for inclusion . 
h Assuming subject is awake, resting, and supine; for adverse event, 3 measurements on the same arm with concordant results.  
 
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   104 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 LABORATORY ELIGIBILITY AND TOXICITY 
RANGES  
For use by DEPRU Core Laboratory  
 Reference 
Range  LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
Blood, Serum, or Plasma Chemistries d 
Sodium (mmol/L)  
135 – 146 LO < LLN - 132 131 - 130 < 130 
HI > ULN - 148 149 - 150 > 150 
Potassium (mmol/L)  
3.4 – 4.6 LO < LLN - 3.1 < 3.1 - 3.0 < 3.0 
HI > ULN - 5.2 5.3 - 5.4 > 5.4 
Bicarbonate/CO2 (mmol/L)  
23 – 34 LO 22 - 17 16 - 12 < 12 
HI > ULN - 35 36 - 40 > 40 
Glucose (mg/dL)  
70 - 99 e LO 69 - 65 64 - 55 < 55 
HI > ULN - 120 121 - 130 > 130 
70 – 140 f HI 141 - 159 160 - 200 > 200 
Blood Urea Nitrogen (mg/dL)  
5-37 HI > ULN - 41 42-46 > 46 
Creatinine (mg/dL)  
0.5 – 1.2 HI > ULN - 1.7 1.8 - 2.0 > 2.0 
eGFR (mL/min/1.73 m2) 
by Modification of Diet in 
Renal Disease (MDRD) 
equation  ≥ 60 
mL/min/1.73 
m2 LO 59 - 45 44 - 30 < 30 
Calcium (mg/dL)  
8.3 - 10.6 LO < LLN - 8.0 7.9 - 7.5 < 7.5 
HI > ULN - 11.0 11.1 - 11.5 > 11.5 
Albumin (g/dL)  3.8 - 5.1 LO 3.7 - 2.8 2.7 - 2.5 < 2.5 
Total Protein (g/dL)  5.9 – 8.3 LO < LLN - 5.5 5.4 - 5.0 < 5.0 
Alkaline Phosphatase (U/L)  34 – 138 N 139 - 240 241 - 360 > 360 
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   105 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  Reference 
Range  LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
AST (U/L) 6 – 40 HI 41 - 105 106 - 175 > 175 
ALT (U/L) Female: 6-35 HI 36 – 105 106 – 175 > 175 
Male: 6-40 HI 41 - 105 106 - 175 > 175 
 
Bilirubin, Serum Total 
(mg/dL)  0.2-1.0 HI 1.1 - 2.0 2.1 - 2.5 > 2.5 
Hematology d 
Hemoglobin (g/dL) 
     Females  12.0 – 15.5 LO 11.9 - 11.0 10.9 - 9.5 < 9.5 
     Males  13.7 – 17.3 LO 13.6 - 12.0 11.9 - 10.0 < 10.0 
WBC (109/L) 
3.2 – 9.8 LO 3.19 - 2.50 2.49 - 1.50 < 1.50 
HI 9.90 – 14.99  15.00 - 20.00  > 20.00  
Lymphocytes (109/L) 0.6 – 4.2 LO 0.59 – 0.50 0.49 - 0.40 < 0.40 
Neutrophils (109/L) 2.0 – 8.6 LO 1.99 - 1.50 1.49 - 1.00 < 1.00 
Eosinophils (109)/L 0.00-0.70 HI 0.71 - 0.75 0.76 - 1.50 > 1.50 
Platelets (109/L) 150 – 450 LO 149 - 120 119 - 100 < 100 
Urine  
Protein  Negative  HI 1+ 2+ > 2+ 
Glucose  Negative  HI 1+ 2+ > 2+ 
Bilirubin  Negative  HI 1+ 2+ > 2+ 
Nitrite  Negative  HI Positive  N/A N/A 
Blood (microscopic) —red 
blood cells per high power 
field (rbc/hpf)  0 – 3 HI 4 - 10 11 - 50 > 50 and/or 
gross blood  
WBC (microscopic) —white 
blood cells per high power 
field (wbc/hpf)  0 – 5 HI 6 - 10 11 - 50 > 50 and/or 
gross blood  
Urobilinogen (mg/dL)  0.2 – 1.0 HI > ULN – 1.5 1.6 – 2.0 > 2.0  
DMID Protocol 18 -0006 Version 1 1.0 
Phase 1 Study of SAR440894 vs Placebo  15 August  2023  
________________________________ ________________________________ ________________________________ ________  
 
DMID/NIAID/NIH   106 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  Reference 
Range  LO/HI/N b  Mild  
(Grade 1) c Moderate 
(Grade 2)  Severe  
(Grade 3)  
Note: This table is to be used for subjects who screened and enrolled prior to Protocol Version 11.0. Subjects who screen and 
enroll with Protocol Version 11.0, toxicity will be assessed with the  NCI CTCAE, Version 5.0 – November  2017 . 
a Reference range of DEPRU Core  laboratory.  
b High, Low, Not Graded.  
c If initial bound of Grade 1 has gap from reference range, calculations based on New England Journal of Medicine  reference 
ranges.  
d Depending upon the lab used, references ranges and gra ding may be split out by sex and/or age.  
e Fasting  > 8 hours 
f Nonfasting ; includes subjects fasting ≥ 2 h ours and < 8 hours .  
 